Semaglutide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 8, 2026

The clinical evidence base for Semaglutide comprises 752 peer-reviewed publications across 15 journals, 81 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Obesity, Metabolic Syndrome, and Diabetes Mellitus. Most recent publication: Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial., Lancet Diabetes Endocrinol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Endovascular Therapy for Acute Stroke with a Large Ischemic Region.
Yoshimura S, Sakai N, Yamagami H, et al. · N Engl J Med · 2022
PubMed: PMID 35138767 · NCT07030621 (STARS) · Ischemic Stroke
Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. · N Engl J Med · 2022
PubMed: PMID 36322838 · NCT04102189 · Obesity
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y, Bao X, Eliaschewitz FG, et al. · Lancet Diabetes Endocrinol · 2024
PubMed: PMID 38330988 · NCT04251156 (STEP7) · Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
McGowan BM, Bruun JM, Capehorn M, et al. · Lancet Diabetes Endocrinol · 2024
PubMed: PMID 39089293 · NCT05040971 (STEP 10) · Obesity
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · N Engl J Med · 2023
PubMed: PMID 37952131 · NCT03574597 (SELECT) · Obesity
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · N Engl J Med · 2023
PubMed: PMID 37622681 · NCT04788511 (STEP-HFpEF) · Obesity
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Bliddal H, Bays H, Czernichow S, et al. · N Engl J Med · 2024
PubMed: PMID 39476339 · NCT05064735 · Obesity
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Aroda VR, Aberle J, Bardtrum L, et al. · Lancet · 2023
PubMed: PMID 37385279 · NCT04707469 (PIONEER PLUS) · Diabetes Mellitus, Type 2

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT01720446 SUSTAIN™ 6	Diabetes Mellitus, Type 2	Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke Time from randomisation up to end of follow-up (scheduled at week 109)	Placebo	8.9 percentage of subjects
NCT01720446 SUSTAIN™ 6	Diabetes Mellitus, Type 2		Semaglutide	6.6 percentage of subjects
NCT01885208 SUSTAIN™ 3	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Week 0, week 56	Exenatide ER 2.0 mg	-0.92 percentage of glycosylated haemoglobin (±0.06 Standard Error)
NCT01885208 SUSTAIN™ 3	Diabetes Mellitus, Type 2		Semaglutide 1.0 mg	-1.54 percentage of glycosylated haemoglobin (±0.06 Standard Error)
NCT01930188 SUSTAIN™ 2	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) From Baseline Week 0, week 56	Semaglutide 0.5 mg + Sitagliptin Placebo	-1.32 percentage of glycosylated haemoglobin (±0.05 Standard Error)
			Semaglutide 1.0 mg + Sitagliptin Placebo	-1.61 percentage of glycosylated haemoglobin (±0.05 Standard Error)
			Sitagliptin + Semaglutide Placebo	-0.55 percentage of glycosylated haemoglobin (±0.05 Standard Error)
NCT02054897 SUSTAIN™1	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, week 30	Placebo	-0.00 Percentage of HbA1c (±0.90 Standard Deviation)
			Semaglutide 0.5 mg	-1.47 Percentage of HbA1c (±1.02 Standard Deviation)
			Semaglutide 1.0 mg	-1.56 Percentage of HbA1c (±1.26 Standard Deviation)
NCT02128932 SUSTAIN™ 4	Diabetes Mellitus, Type 2	Change in HbA1c From Baseline Week 0, week 30	Insulin Glargine	-0.83 percentage (±0.05 Standard Error)
			Semaglutide 0.5mg/Week	-1.21 percentage (±0.05 Standard Error)
			Semaglutide 1.0 mg/Week	-1.64 percentage (±0.05 Standard Error)
NCT02207374 SUSTAIN™	Diabetes Mellitus, Type 2	Number of Treatment Emergent Adverse Events (TEAEs) Weeks 0-56	Additional OAD	269 Number of events
			Semaglutide 0.5 mg	909 Number of events
			Semaglutide 1.0 mg	954 Number of events
NCT02254291 SUSTAIN™	Diabetes Mellitus, Type 2	Number of Treatment Emergent Adverse Events (TEAEs) Weeks 0-30	Semaglutide 0.5 mg	228 Number of events
			Semaglutide 1.0 mg	197 Number of events
			Sitagliptin	186 Number of events
NCT02305381 SUSTAIN™ 5	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, week 30	Placebo	-0.09 percentage of glycosylated hemoglobin (±0.09 Standard Error)
			Semaglutide 0.5 mg	-1.45 percentage of glycosylated hemoglobin (±0.09 Standard Error)
			Semaglutide 1.0 mg	-1.85 percentage of glycosylated hemoglobin (±0.09 Standard Error)
NCT02607865 PIONEER 3	Diabetes Mellitus, Type 2	Change in HbA1c: Week 26 Week 0, week 26	Oral Semaglutide 14 mg	-1.4 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 14 mg	-1.3 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-0.6 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-0.6 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.2 Percentage of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 7 mg	-1.1 Percentage of HbA1c (±1.1 Standard Deviation)
			Sitagliptin 100 mg	-0.8 Percentage of HbA1c (±0.9 Standard Deviation)
			Sitagliptin 100 mg	-0.8 Percentage of HbA1c (±0.9 Standard Deviation)
NCT02648204 SUSTAIN 7	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 40	Dulaglutide 0.75 mg	-1.11 percentage of HbA1c (±0.05 Standard Error)
			Dulaglutide 1.5 mg	-1.37 percentage of HbA1c (±0.06 Standard Error)
			Semaglutide 0.5 mg	-1.51 percentage of HbA1c (±0.06 Standard Error)
			Semaglutide 1.0 mg	-1.78 percentage of HbA1c (±0.06 Standard Error)
NCT02692716 PIONEER 6	Diabetes Mellitus, Type 2	Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.	Oral Semaglutide	61 Participants
NCT02692716 PIONEER 6	Diabetes Mellitus, Type 2		Placebo	76 Participants
NCT02827708 PIONEER 5	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Oral Semaglutide 14 mg	-1.1 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 14 mg	-1.2 Percentage of HbA1c (±0.9 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.9 Standard Deviation)
			Placebo	-0.2 Percentage of HbA1c (±0.9 Standard Deviation)
NCT02849080 PIONEER 7	Diabetes Mellitus, Type 2	Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no) Week 52	Oral Semaglutide Flex- Main Phase	134 Participants
			Oral Semaglutide Flex- Main Phase	96 Participants
			Oral Semaglutide Flex- Main Phase	123 Participants
			Oral Semaglutide Flex- Main Phase	73 Participants
			Sitagliptin 100 mg- Main Phase	52 Participants
			Sitagliptin 100 mg- Main Phase	178 Participants
			Sitagliptin 100 mg- Main Phase	60 Participants
			Sitagliptin 100 mg- Main Phase	132 Participants
NCT02863328 PIONEER 2	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Empagliflozin 25 mg	-0.9 Percentage-point of HbA1c (±0.9 Standard Deviation)
			Empagliflozin 25 mg	-0.9 Percentage-point of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.3 Percentage-point of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 14 mg	-1.5 Percentage-point of HbA1c (±1.1 Standard Deviation)
NCT02863419 PIONEER 4	Diabetes Mellitus, Type 2	Change in HbA1c (Week 26) Week 0, week 26	Liraglutide 1.8 mg	-1.2 Percentage of HbA1c (±0.9 Standard Deviation)
			Liraglutide 1.8 mg	-1.1 Percentage of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.4 Percentage of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.2 Percentage of HbA1c (±0.9 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.7 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.7 Standard Deviation)
NCT02906930 PIONEER 1	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Oral Semaglutide 14 mg	-1.5 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 14 mg	-1.6 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-0.9 Percentage of HbA1c (±1.2 Standard Deviation)
			Oral Semaglutide 3 mg	-0.9 Percentage of HbA1c (±1.2 Standard Deviation)
			Oral Semaglutide 7 mg	-1.3 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.4 Percentage of HbA1c (±0.9 Standard Deviation)
			Placebo	-0.3 Percentage of HbA1c (±1.2 Standard Deviation)
			Placebo	-0.3 Percentage of HbA1c (±1.2 Standard Deviation)
NCT03015220 PIONEER 10	Diabetes Mellitus, Type 2	Number of Treatment-emergent Adverse Events (TEAEs) Weeks 0-57	Dulaglutide 0.75 mg	178 Events
			Oral Semaglutide 14 mg	324 Events
			Oral Semaglutide 3 mg	330 Events
			Oral Semaglutide 7 mg	350 Events
NCT03018028 PIONEER 9	Diabetes Mellitus, Type 2	Change in HbA1c (Week 26) Week 0, week 26	Liraglutide 0.9 mg	-1.4 Percentage point of HbA1c (±1.1 Standard Deviation)
			Liraglutide 0.9 mg	-1.4 Percentage point of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 14 mg	-1.7 Percentage point of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.7 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 3 mg	-1.1 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 3 mg	-1.1 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 7 mg	-1.7 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 7 mg	-1.6 Percentage point of HbA1c (±0.8 Standard Deviation)
			Placebo	-0.2 Percentage point of HbA1c (±0.7 Standard Deviation)
			Placebo	-0.4 Percentage point of HbA1c (±1.0 Standard Deviation)
NCT03021187 PIONEER 8	Diabetes Mellitus, Type 2	Change in HbA1c (Week 26) Week 0, week 26	Oral Semaglutide 14 mg	-1.4 Percentage of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.3 Percentage of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 3 mg	-0.6 Percentage of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 3 mg	-0.5 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.1 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.0 Percentage of HbA1c (±1.1 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.8 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.9 Standard Deviation)
NCT03061214 SUSTAIN	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Semaglutide 0.5 mg	-1.5 Percentage of glycosylated haemoglobin (±1.1 Standard Deviation)
			Semaglutide 0.5 mg	-1.5 Percentage of glycosylated haemoglobin (±1.1 Standard Deviation)
			Semaglutide 1.0 mg	-1.8 Percentage of glycosylated haemoglobin (±0.9 Standard Deviation)
			Semaglutide 1.0 mg	-1.7 Percentage of glycosylated haemoglobin (±1.0 Standard Deviation)
			Sitagliptin	-0.9 Percentage of glycosylated haemoglobin (±0.9 Standard Deviation)
			Sitagliptin	-1.0 Percentage of glycosylated haemoglobin (±0.9 Standard Deviation)
NCT03086330 SUSTAIN 9	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Placebo	-0.2 Percentage of HbA1c (±0.9 Standard Deviation)
NCT03086330 SUSTAIN 9	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Semaglutide 1.0 mg	-1.6 Percentage of HbA1c (±0.8 Standard Deviation)
NCT03136484 SUSTAIN 8	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 52	Canagliflozin + Semaglutide Placebo	-1.0 Percentage (%) of HbA1c (±1.1 Standard Deviation)
			Canagliflozin + Semaglutide Placebo	-1.0 Percentage (%) of HbA1c (±1.0 Standard Deviation)
			Semaglutide + Canagliflozin Placebo	-1.7 Percentage (%) of HbA1c (±1.1 Standard Deviation)
			Semaglutide + Canagliflozin Placebo	-1.5 Percentage (%) of HbA1c (±1.3 Standard Deviation)
NCT03191396 SUSTAIN 10	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Liraglutide 1.2 mg	-1.1 Percentage of glycosylated haemoglobin (±1.0 Standard Deviation)
NCT03191396 SUSTAIN 10	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Semaglutide 1.0 mg	-1.7 Percentage of glycosylated haemoglobin (±0.9 Standard Deviation)
NCT03548935 STEP 1	Obesity	Change in Body Weight (%) Baseline (week 0) to week 68	Placebo	-2.8 Percentage point (±6.5 Standard Deviation)
			Placebo	-3.1 Percentage point (±6.4 Standard Deviation)
			Semaglutide 2.4 mg	-16.9 Percentage point (±9.4 Standard Deviation)
			Semaglutide 2.4 mg	-15.6 Percentage point (±10.1 Standard Deviation)
NCT03548935 STEP 1	Obesity	Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no) After week 68	Placebo	182 Participants
			Placebo	334 Participants
			Placebo	395 Participants
			Placebo	165 Participants
			Semaglutide 2.4 mg	165 Participants
			Semaglutide 2.4 mg	978 Participants
			Semaglutide 2.4 mg	81 Participants
			Semaglutide 2.4 mg	1047 Participants
NCT03548987 STEP 4	Obesity	Change From Randomisation to Week 68 in Body Weight (%) Randomisation (week 20) to week 68	Placebo	6.1 Percentage point (±7.7 Standard Deviation)
			Placebo	6.5 Percentage point (±7.7 Standard Deviation)
			Semaglutide 2.4 mg	-8.8 Percentage point (±7.8 Standard Deviation)
			Semaglutide 2.4 mg	-8.3 Percentage point (±8.1 Standard Deviation)
NCT03552757 STEP 2	Obesity	Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo Baseline (week 0) to week 68	Placebo	-3.3 Percentage point of body weight (±5.5 Standard Deviation)
			Placebo	-3.1 Percentage point of body weight (±5.2 Standard Deviation)
			Semaglutide 2.4 mg	-10.7 Percentage point of body weight (±7.8 Standard Deviation)
			Semaglutide 2.4 mg	-9.9 Percentage point of body weight (±8.0 Standard Deviation)
NCT03552757 STEP 2	Obesity	Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo At week 68	Placebo	107 Participants
			Placebo	269 Participants
			Placebo	94 Participants
			Placebo	246 Participants
			Semaglutide 2.4 mg	267 Participants
			Semaglutide 2.4 mg	121 Participants
			Semaglutide 2.4 mg	257 Participants
			Semaglutide 2.4 mg	94 Participants
NCT03574597 SELECT	Obesity	Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke From randomisation (week 0) up to 240 weeks	Placebo	701 Participants
NCT03574597 SELECT	Obesity		Semaglutide	569 Participants
NCT03611582 STEP 3	Obesity	Change in Body Weight (%) Baseline (week 0) to week 68	Placebo	-6.1 Percentage (±7.6 Standard Deviation)
			Placebo	-5.8 Percentage (±7.7 Standard Deviation)
			Semaglutide 2.4 mg	-17.6 Percentage (±9.6 Standard Deviation)
			Semaglutide 2.4 mg	-16.5 Percentage (±10.1 Standard Deviation)
NCT03611582 STEP 3	Obesity	Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5% After 68 weeks	Placebo	82 Participants
			Placebo	90 Participants
			Placebo	82 Participants
			Placebo	99 Participants
			Semaglutide 2.4 mg	50 Participants
			Semaglutide 2.4 mg	34 Participants
			Semaglutide 2.4 mg	323 Participants
			Semaglutide 2.4 mg	300 Participants
NCT03689374 SUSTAIN 11	Diabetes Mellitus, Type 2	Change From Baseline in Glycated Haemoglobin (HbA1c) Baseline (week 0), week 52	Insulin Aspart	-1.2 Percentage of HbA1c (±1.0 Standard Deviation)
NCT03689374 SUSTAIN 11	Diabetes Mellitus, Type 2		Semaglutide	-1.5 Percentage of HbA1c (±1.0 Standard Deviation)
NCT03693430 STEP 5	Obesity	Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5% At Week 104	Placebo	44 Participants
			Placebo	84 Participants
			Placebo	38 Participants
			Placebo	71 Participants
			Semaglutide 2.4 mg	110 Participants
			Semaglutide 2.4 mg	111 Participants
			Semaglutide 2.4 mg	33 Participants
			Semaglutide 2.4 mg	22 Participants
NCT03693430 STEP 5	Obesity	Percentage Change From Baseline (Week 0) to Week 104 in Body Weight From Baseline (Week 0) to Week 104	Placebo	-1.9 percentage change (±8.9 Standard Deviation)
			Placebo	-2.0 percentage change (±8.6 Standard Deviation)
			Semaglutide 2.4 mg	-15.9 percentage change (±12.3 Standard Deviation)
			Semaglutide 2.4 mg	-17.3 percentage change (±11.9 Standard Deviation)
NCT03811574 STEP 6	Obesity	Change in Body Weight (%) Baseline (week 0), week 68	Placebo	-1.9 Percentage change (±5.9 Standard Deviation)
			Semaglutide 1.7 mg	-9.9 Percentage change (±7.8 Standard Deviation)
			Semaglutide 2.4 mg	-13.4 Percentage change (±8.6 Standard Deviation)
NCT03811574 STEP 6	Obesity	Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5% At week 68	Placebo	21 Participants
			Placebo	79 Participants
			Semaglutide 1.7 mg	71 Participants
			Semaglutide 1.7 mg	27 Participants
			Semaglutide 2.4 mg	33 Participants
			Semaglutide 2.4 mg	160 Participants
NCT03819153 FLOW	Diabetes Mellitus, Type 2	Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death From Week 0 up to Week 234	Placebo	410 Participants
NCT03819153 FLOW	Diabetes Mellitus, Type 2		Semaglutide	331 Participants
NCT03914326 SOUL	Diabetes Mellitus, Type 2	Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke From randomisation (week 0) up to week 265	Oral Semaglutide	579 Participants
NCT03914326 SOUL	Diabetes Mellitus, Type 2		Placebo	668 Participants
NCT03919929 TEAL	Non-alcoholic Fatty Liver Disease	Change in Hepatic Fat Fraction Baseline and 12 weeks	Diet Intervention	-1.41 Change in percentage of liver fat (±2.24 Standard Deviation)
NCT03919929 TEAL	Non-alcoholic Fatty Liver Disease	Change in Hepatic Fat Fraction Baseline and 12 weeks	GLP-1 Intervention	-1.84 Change in percentage of liver fat (±4.39 Standard Deviation)
NCT03919929 TEAL	Non-alcoholic Fatty Liver Disease	Change in Weight Baseline and 12 weeks	Diet Intervention	-1.66 Change in weight (KG) (±2.81 Standard Deviation)
NCT03919929 TEAL	Non-alcoholic Fatty Liver Disease	Change in Weight Baseline and 12 weeks	GLP-1 Intervention	-5.30 Change in weight (KG) (±4.92 Standard Deviation)
NCT03987919 SURPASS-2	Diabetes Mellitus, Type 2	Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) Baseline, Week 40	1 mg Semaglutide	-1.86 Percentage of HbA1c (±0.048 Standard Error)
			10 mg Tirzepatide	-2.37 Percentage of HbA1c (±0.048 Standard Error)
			15 mg Tirzepatide	-2.46 Percentage of HbA1c (±0.048 Standard Error)
NCT03989232 SUSTAIN FORTE	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 40	Semaglutide 1.0 mg	-1.9 Percentage change (±1.0 Standard Deviation)
			Semaglutide 1.0 mg	-2.0 Percentage change (±1.0 Standard Deviation)
			Semaglutide 2.0 mg	-2.2 Percentage change (±1.0 Standard Deviation)
			Semaglutide 2.0 mg	-2.2 Percentage change (±1.1 Standard Deviation)
NCT04017832 PIONEER 12	Diabetes Mellitus, Type 2	Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%) From baseline to week 26	Oral Semaglutide 14 mg	-1.5 Percentage point of HbA1C (±1.0 Standard Deviation)
			Oral Semaglutide 14 mg	-1.6 Percentage point of HbA1C (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-0.8 Percentage point of HbA1C (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-0.8 Percentage point of HbA1C (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.3 Percentage point of HbA1C (±1.0 Standard Deviation)
			Oral Semaglutide 7 mg	-1.3 Percentage point of HbA1C (±1.0 Standard Deviation)
			Sitagliptin 100 mg	-0.7 Percentage point of HbA1C (±1.0 Standard Deviation)
			Sitagliptin 100 mg	-0.7 Percentage point of HbA1C (±1.0 Standard Deviation)
NCT04074161 STEP 8	Obesity	Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Baseline (week 0), week 68	Liraglutide 3.0 mg	-6.4 Percentage of body weight (±7.7 Standard Deviation)
NCT04074161 STEP 8	Obesity		Semaglutide 2.4 mg	-16.4 Percentage of body weight (±10.5 Standard Deviation)
NCT04102189	Obesity	Change in Body Mass Index (BMI) (Percentage [%]) Baseline (week 0), week 68	Placebo	-0.1 Percentage change of BMI (±8.6 Standard Deviation)
NCT04102189	Obesity		Semaglutide 2.4 mg	-16.2 Percentage change of BMI (±12.9 Standard Deviation)
NCT04109547 PIONEER 11	Diabetes Mellitus, Type 2	Change From Baseline in Glycosylated Haemoglobin (HbA1c) Baseline (Week 0), Week 26	Oral Semaglutide 14 mg	-1.6 Percentage of HbA1c (±1.0 Standard Deviation)
			Oral Semaglutide 3 mg	-1.1 Percentage of HbA1c (±0.7 Standard Deviation)
			Oral Semaglutide 7 mg	-1.5 Percentage of HbA1c (±0.8 Standard Deviation)
			Placebo	-0.2 Percentage of HbA1c (±0.9 Standard Deviation)
NCT04251156 STEP7	Diabetes Mellitus, Type 2	Change From Baseline in Body Weight (Percentage [%]) Baseline (week 0), week 44	Placebo	-3.6 Percentage change (±5.9 Standard Deviation)
NCT04251156 STEP7	Diabetes Mellitus, Type 2		Semaglutide 2.4 mg	-12.5 Percentage change (±7.4 Standard Deviation)
NCT04251156 STEP7	Diabetes Mellitus, Type 2	Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No) At week 44	Placebo	36 Participants
			Placebo	80 Participants
			Semaglutide 2.4 mg	203 Participants
			Semaglutide 2.4 mg	35 Participants
NCT04560998 STRIDE	Diabetes Mellitus, Type 2	Change in Maximum Walking Distance on a Constant Load Treadmill Test Baseline (week 0), end of treatment (week 52)	Placebo	1.08 Ratio of maximum walking distance
NCT04560998 STRIDE	Diabetes Mellitus, Type 2		Semaglutide	1.21 Ratio of maximum walking distance
NCT04707469 PIONEER PLUS	Diabetes Mellitus, Type 2	Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) Baseline (week 0), week 52	Oral Semaglutide 14 mg	-1.5 Percentage point of HbA1c (±1.3 Standard Deviation)
			Oral Semaglutide 25 mg	-1.9 Percentage point of HbA1c (±1.3 Standard Deviation)
			Oral Semaglutide 50 mg	-2.1 Percentage point of HbA1c (±1.4 Standard Deviation)
NCT04741074 RAISE-KT	Obesity	Kidney Transplant Eligibility Ascertained at the end of 9 months	Placebo	2 Participants
NCT04741074 RAISE-KT	Obesity		Semaglutide	3 Participants
NCT04788511 STEP-HFpEF	Obesity	Change in Body Weight From baseline (week 0) to end of treatment (week 52)	Placebo	-2.5 Percentage of body weight (±5.6 Standard Deviation)
NCT04788511 STEP-HFpEF	Obesity		Semaglutide 2.4 mg	-13.9 Percentage of body weight (±8.1 Standard Deviation)
NCT04788511 STEP-HFpEF	Obesity	Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) From baseline (week 0) to end of treatment (week 52)	Placebo	10.3 Score on a scale (±17.3 Standard Deviation)
NCT04788511 STEP-HFpEF	Obesity		Semaglutide 2.4 mg	16.8 Score on a scale (±17.9 Standard Deviation)
NCT04865770 REMODEL	Diabetes Mellitus, Type 2	Change in Global Kidney Perfusion (MRI) Baseline (week 0), End of treatment (week 52)	Placebo	1.01 Ratio of global kidney perfusion (±26.83 Geometric Coefficient of Variation)
			Placebo	0.98 Ratio of global kidney perfusion (±28.85 Geometric Coefficient of Variation)
			Placebo	0.99 Ratio of global kidney perfusion (±24.39 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.03 Ratio of global kidney perfusion (±26.43 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.02 Ratio of global kidney perfusion (±29.25 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.04 Ratio of global kidney perfusion (±27.84 Geometric Coefficient of Variation)
NCT04865770 REMODEL	Diabetes Mellitus, Type 2	Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI) Baseline (week 0), End of treatment (week 52)	Placebo	1.01 Ratio of kidney inflammation (cortex) (±5.43 Geometric Coefficient of Variation)
			Placebo	1.01 Ratio of kidney inflammation (cortex) (±5.71 Geometric Coefficient of Variation)
			Placebo	1.01 Ratio of kidney inflammation (cortex) (±5.57 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.01 Ratio of kidney inflammation (cortex) (±3.93 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.01 Ratio of kidney inflammation (cortex) (±3.88 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.01 Ratio of kidney inflammation (cortex) (±3.78 Geometric Coefficient of Variation)
NCT04865770 REMODEL	Diabetes Mellitus, Type 2	Change in Kidney Inflammation (Medulla), T1 Mapping (MRI) Baseline (week 0), End of treatment (week 52)	Placebo	1.00 Ratio of kidney inflammation (medulla) (±5.91 Geometric Coefficient of Variation)
			Placebo	1.00 Ratio of kidney inflammation (medulla) (±5.13 Geometric Coefficient of Variation)
			Placebo	1.01 Ratio of kidney inflammation (medulla) (±4.85 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.00 Ratio of kidney inflammation (medulla) (±3.56 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.00 Ratio of kidney inflammation (medulla) (±3.90 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	1.00 Ratio of kidney inflammation (medulla) (±3.69 Geometric Coefficient of Variation)
NCT04865770 REMODEL	Diabetes Mellitus, Type 2	Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) Baseline (week 0), End of treatment (week 52)	Placebo	1.00 Ratio of kidney oxygenation (cortex) (±7.39 Geometric Coefficient of Variation)
			Placebo	1.01 Ratio of kidney oxygenation (cortex) (±9.12 Geometric Coefficient of Variation)
			Placebo	0.99 Ratio of kidney oxygenation (cortex) (±7.26 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.98 Ratio of kidney oxygenation (cortex) (±5.35 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.98 Ratio of kidney oxygenation (cortex) (±7.51 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.98 Ratio of kidney oxygenation (cortex) (±5.65 Geometric Coefficient of Variation)
NCT04865770 REMODEL	Diabetes Mellitus, Type 2	Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*) Baseline (week 0), End of treatment (week 52)	Placebo	1.01 Ratio of kidney oxygenation (medulla) (±11.37 Geometric Coefficient of Variation)
			Placebo	1.02 Ratio of kidney oxygenation (medulla) (±13.02 Geometric Coefficient of Variation)
			Placebo	1.02 Ratio of kidney oxygenation (medulla) (±10.83 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.99 Ratio of kidney oxygenation (medulla) (±10.25 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.99 Ratio of kidney oxygenation (medulla) (±8.97 Geometric Coefficient of Variation)
			Semaglutide 1.0 mg	0.98 Ratio of kidney oxygenation (medulla) (±10.09 Geometric Coefficient of Variation)
NCT04998136	Obesity	Change in Body Weight (%) : In-trial Observation Period Baseline (week 0), end of treatment (week 44)	Placebo	-2.6 Percentage of body weight (±5.8 Standard Deviation)
NCT04998136	Obesity		Semaglutide	-16.4 Percentage of body weight (±7.3 Standard Deviation)
NCT04998136	Obesity	Change in Body Weight (%) : On-treatment Observation Period Baseline (week 0), end of treatment (week 44)	Placebo	-2.7 Percentage of body weight (±5.8 Standard Deviation)
NCT04998136	Obesity		Semaglutide	-16.4 Percentage of body weight (±7.4 Standard Deviation)
NCT04998136	Obesity	Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period At week 44	Placebo	12 Participants
			Placebo	36 Participants
			Semaglutide	4 Participants
			Semaglutide	96 Participants
NCT04998136	Obesity	Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period At week 44	Placebo	35 Participants
			Placebo	12 Participants
			Semaglutide	92 Participants
			Semaglutide	4 Participants
NCT05035095 OASIS 1	Obesity	Number of Participants Who Achieved Weight Loss Greater Than or Equal (≥) 5% (Yes/No) At end-of-treatment (week 68)	Oral Semaglutide 50 mg	48 Participants
			Oral Semaglutide 50 mg	269 Participants
			Placebo	76 Participants
			Placebo	219 Participants
NCT05035095 OASIS 1	Obesity	Percentage Change in Body Weight Baseline (week 0), end-of-treatment (week 68)	Oral Semaglutide 50 mg	-15.8 Percentage (%) change in body weight (±10.3 Standard Deviation)
NCT05035095 OASIS 1	Obesity		Placebo	-2.2 Percentage (%) change in body weight (±7.2 Standard Deviation)
NCT05040971 STEP 10	Obesity	Change in Body Weight (Percentage [%]) From randomisation (week 0) to end of treatment (week 52)	Placebo	-2.7 Percentage (%) of body weight (±4.3 Standard Deviation)
NCT05040971 STEP 10	Obesity		Semaglutide 2.4 mg	-14.4 Percentage (%) of body weight (±7.9 Standard Deviation)
NCT05040971 STEP 10	Obesity	Participants With Change to Normoglycemia At week 52	Placebo	53 Participants
			Placebo	9 Participants
			Placebo	2 Participants
			Semaglutide 2.4 mg	23 Participants
			Semaglutide 2.4 mg	103 Participants
			Semaglutide 2.4 mg	1 Participants
NCT05064735	Obesity	Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score Baseline (week 0), end of treatment (week 68)	Placebo	-26.2 Score on a scale (±25.0 Standard Deviation)
NCT05064735	Obesity		Semaglutide 2.4 mg	-43.7 Score on a scale (±25.3 Standard Deviation)
NCT05064735	Obesity	Percentage Change in Body Weight Baseline (week 0), end of treatment (week 68)	Placebo	-2.5 Percentage change in body weight (±5.6 Standard Deviation)
NCT05064735	Obesity		Semaglutide 2.4 mg	-14.2 Percentage change in body weight (±8.6 Standard Deviation)
NCT05259033 COMBINE 2	Diabetes Mellitus, Type 2	Change From Baseline in Glycosylated Haemoglobin (HbA1c) Baseline (week 0), (week 52)	IcoSema	-1.40 Percentage point of HbA1c (±0.91 Standard Deviation)
NCT05259033 COMBINE 2	Diabetes Mellitus, Type 2		Semaglutide	-0.86 Percentage point of HbA1c (±0.96 Standard Deviation)
NCT05478252	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) From baseline (week 0) to end of treatment (week 28)	Semaglutide B	-1.6 Percentage of glycosylated haemoglobin (±1.0 Standard Deviation)
NCT05478252	Diabetes Mellitus, Type 2		Semaglutide J	-1.7 Percentage of glycosylated haemoglobin (±1.0 Standard Deviation)
NCT05564117 OASIS 4	Obesity	Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No) At end of treatment (week 64)	Oral Semaglutide 25 mg	40 Participants
			Oral Semaglutide 25 mg	152 Participants
			Placebo	62 Participants
			Placebo	28 Participants
NCT05564117 OASIS 4	Obesity	Percentage Change in Body Weight Baseline (week 0), end of treatment (week 64)	Oral Semaglutide 25 mg	-14.4 Percentage change in body weight (±10.5 Standard Deviation)
NCT05564117 OASIS 4	Obesity		Placebo	-2.5 Percentage change in body weight (±7.9 Standard Deviation)
NCT05646706 STEP UP	Obesity	Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) At week 72	Placebo	108 Participants
			Placebo	63 Participants
			Semaglutide 7.2 mg	862 Participants
			Semaglutide 7.2 mg	88 Participants
NCT05646706 STEP UP	Obesity	Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight Baseline (week 0), End of treatment (week 72)	Placebo	-3.8 Percentage (%) change in body weight (±7.1 Standard Deviation)
NCT05646706 STEP UP	Obesity		Semaglutide 7.2 mg	-19.5 Percentage (%) change in body weight (±10.6 Standard Deviation)
NCT05649137	Diabetes Mellitus, Type 2	Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) At week 72	Placebo	62 Participants
			Placebo	33 Participants
			Semaglutide 2.4 mg	24 Participants
			Semaglutide 2.4 mg	73 Participants
			Semaglutide 7.2 mg	251 Participants
			Semaglutide 7.2 mg	40 Participants
NCT05649137	Diabetes Mellitus, Type 2	Relative Change in Body Weight Baseline (week 0), End of treatment (week 72)	Placebo	-4.0 Percentage (%) change in body weight (±6.2 Standard Deviation)
			Semaglutide 2.4 mg	-10.7 Percentage (%) change in body weight (±8.1 Standard Deviation)
			Semaglutide 7.2 mg	-13.5 Percentage (%) change in body weight (±8.7 Standard Deviation)
NCT05788965	Cystic Fibrosis	BMI (kg/m2) 12 weeks	Semaglutide Treatment	-1.8 kg/m2 (±0.9 Standard Deviation)
NCT05788965	Cystic Fibrosis	Weight 12 weeks	Semaglutide Treatment	-4.6 kilograms (±1.9 Standard Deviation)
NCT05822830 SURMOUNT-5	Obesity	Percent Change From Baseline in Body Weight Baseline, Week 72	15 mg or MTD - Tirzepatide	-20.2 Percent change (±0.59 Standard Error)
NCT05822830 SURMOUNT-5	Obesity		2.4 mg or MTD - Semaglutide	-13.7 Percent change (±0.59 Standard Error)
NCT05891496	Alzheimer Disease	Change in Gene Expression Assessed by scRNAseq (Cells in Blood) Baseline (week 0), week 12	Placebo	16.50 Differentially expressed genes (±15.86 Standard Deviation)
NCT05891496	Alzheimer Disease		Semaglutide	10.00 Differentially expressed genes (±5.97 Standard Deviation)
NCT05891496	Alzheimer Disease	Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) Baseline (week 0), week 12	Placebo	21.00 Differentially expressed genes (±25.70 Standard Deviation)
NCT05891496	Alzheimer Disease		Semaglutide	41.25 Differentially expressed genes (±29.68 Standard Deviation)

Publications by year

1972–2026: 752 publications.

1972

1983

1985

1987

1988

1992

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Diabetes Mellitus, Type 2 (265)

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
Diabetes Ther · 2026 · PMID 41848818 · NCT06351748
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.
Clin J Am Soc Nephrol · 2026 · PMID 41706532 · NCT03819153
Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.
JAMA Psychiatry · 2026 · PMID 41335431 · NCT04892199
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Cardiovasc Diabetol · 2026 · PMID 41422027 · NCT03819153
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet · 2026 · PMID 41765029 · NCT06045221

Obesity (182)

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Lancet Diabetes Endocrinol · 2026 · PMID 42009015 · NCT05813925
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Hypertension · 2026 · PMID 41328546 · NCT05567796
Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma.
J Allergy Clin Immunol Glob · 2026 · PMID 41567689 · NCT05254314
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
JAMA Cardiol · 2026 · PMID 41433034 · NCT03574597
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Nat Med · 2026 · PMID 41928037 · NCT03574597

Metabolic Syndrome (56)

A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design.
Alzheimers Dement (N Y) · 2024 · PMID 32296731 · NCT06072963
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Res Clin Pract · 2023 · PMID 36871874 · NCT06072963
Effect of Metabolic Syndrome on the Incidence of Dementia Based on National Insurance Data in Korea.
Metab Syndr Relat Disord · 2022 · PMID 34756135 · NCT06072963
Safety of Semaglutide.
Front Endocrinol (Lausanne) · 2022 · PMID 34305810 · NCT06072963
Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations.
Stroke Vasc Neurol · 2022 · PMID 33903177 · NCT06072963

Diabetes Mellitus (44)

Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
J Magn Reson Imaging · 2025 · PMID 22025886 · NCT06060392
Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.
Front Endocrinol (Lausanne) · 2025 · PMID 40607222 · NCT05990374
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
JACC Heart Fail · 2025 · PMID 40956259 · NCT04916470
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol · 2025 · PMID 39848268 · NCT04916470
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
JACC Heart Fail · 2025 · PMID 41045908 · NCT04916470

Diabetes Mellitus, Type 1 (33)

Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease.
Expert Rev Clin Immunol · 2025 · PMID 40693871 · NCT05822609
Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
J Am Soc Nephrol · 2024 · PMID 39078403 · NCT06082063
Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
Adv Pharm Bull · 2024 · PMID 39206389 · NCT06057077
Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
Diabetes Obes Metab · 2024 · PMID 34989070 · NCT06894784
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Diabetes Obes Metab · 2023 · PMID 36942888 · NCT06894784

Weight Loss (30)

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Eur J Endocrinol · 2023 · PMID 37318239 · NCT07361874
Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.
Ann Intern Med · 2022 · PMID 34978855 · NCT07361874
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Nat Commun · 2022 · PMID 35970829 · NCT05574439
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses.
Best Pract Res Clin Endocrinol Metab · 2021 · PMID 33593680 · NCT07361874
Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations.
Int J Obes (Lond) · 2021 · PMID 32921795 · NCT05574439

Publications by journal

Diabetes Obes Metab62 papers
Lancet Diabetes Endocrinol30 papers
Diabetes Ther29 papers
N Engl J Med27 papers
Diabetes Care24 papers
Lancet20 papers
J Clin Endocrinol Metab16 papers
Nat Med12 papers
J Am Coll Cardiol11 papers
Adv Ther10 papers

Trial-results highlights

Clinical trials have evaluated semaglutide for the treatment of Type 2 Diabetes Mellitus. In NCT01885208, the change from baseline in HbA1c was -1.54 percentage of glycosylated haemoglobin for the semaglutide 1.0 mg arm, and -0.92 percentage of glycosylated haemoglobin for the Exenatide ER 2.0 mg arm. In NCT01930188, the change in HbA1c from baseline was -1.32 percentage of glycosylated haemoglobin for the semaglutide 0.5 mg + Sitagliptin Placebo arm, -1.61 percentage of glycosylated haemoglobin for the semaglutide 1.0 mg + Sitagliptin Placebo arm, and -0.55 percentage of glycosylated haemoglobin for the Sitagliptin + Semaglutide Placebo arm. In NCT02054897, the change in HbA1c was -1.47 Percentage of HbA1c for the semaglutide 0.5 mg arm and -1.56 Percentage of HbA1c for the semaglutide 1.0 mg arm, compared to -0.00 Percentage of HbA1c for the placebo arm. NCT02128932 reported a change in HbA1c from baseline of -1.21 percentage for the semaglutide 0.5mg/Week arm and -1.64 percentage for the semaglutide 1.0 mg/Week arm, versus -0.83 percentage for the Insulin Glargine arm. In NCT02305381, the change in HbA1c was -1.45 percentage of glycosylated hemoglobin for the semaglutide 0.5 mg arm and -1.85 percentage of glycosylated hemoglobin for the semaglutide 1.0 mg arm, compared to -0.09 percentage of glycosylated hemoglobin for the placebo arm.

The SUSTAIN™ 6 trial (NCT01720446) evaluated the time to first occurrence of a Major Adverse Cardiovascular Event (MACE), defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. In this study, 6.6 percentage of subjects in the semaglutide arm experienced a MACE, compared to 8.9 percentage of subjects in the placebo arm. Regarding Treatment Emergent Adverse Events (TEAEs), NCT02207374 reported 909 events for the semaglutide 0.5 mg arm and 954 events for the semaglutide 1.0 mg arm, compared to 269 events for the Additional OAD arm. Another study, NCT02254291, reported 228 events for the semaglutide 0.5 mg arm and 197 events for the semaglutide 1.0 mg arm, compared to 186 events for the Sitagliptin arm.

All values presented here are sourced from primary registry reporting on ClinicalTrials.gov, and individual published papers should be consulted for comprehensive clinical decision-making.

All Semaglutide publications (752)

2026 (38 papers)

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Yamauchi T, Becker NP, Hagemann CA, et al. · Lancet Diabetes Endocrinol · 2026 · Derived
PubMed: PMID 42009015 · NCT05813925 · Obesity
Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
Wang S, Hu P, Shen Z, et al. · Diabetes Ther · 2026 · Derived
PubMed: PMID 41848818 · NCT06351748 (SCHOLAR) · Diabetes Mellitus, Type 2
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Verma S, Böttcher M, Brown P, et al. · Hypertension · 2026 · Derived
PubMed: PMID 41328546 · NCT05567796 (REDEFINE 1) · Obesity
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.
Tuttle KR, Mann JFE, Mayrdorfer MM, et al. · Clin J Am Soc Nephrol · 2026 · Derived
PubMed: PMID 41706532 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma.
Tomasello A, Bacharier LB, Becker PM, et al. · J Allergy Clin Immunol Glob · 2026 · Derived
PubMed: PMID 41567689 · NCT05254314 (GATA-3) · Obesity
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.
Scheltens P, Atri A, Feldman HH, et al. · Alzheimers Dement (N Y) · 2026 · Derived
PubMed: PMID 41522368 · NCT04777409 (EVOKE Plus)
Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.
Sass MR, Klausen MK, Schwarz CR, et al. · JAMA Psychiatry · 2026 · Derived
PubMed: PMID 41335431 · NCT04892199 · Diabetes Mellitus, Type 2
GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.
Samaranayake CB, Chen YC, Fang M, et al. · Eur Heart J Open · 2026 · Derived
PubMed: PMID 41536961 · NCT06118203 · Pulmonary Embolism
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Rossing P, Lindhardt M, Tikkanen CK, et al. · Cardiovasc Diabetol · 2026 · Derived
PubMed: PMID 41422027 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Rosenstock J, Yabe D, Cox D, et al. · Lancet · 2026 · Derived
PubMed: PMID 41765029 · NCT06045221 (ACHIEVE-3) · Diabetes Mellitus, Type 2
Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.
Rayner B, Mahaffey KW, Mann JFE, et al. · Nephrol Dial Transplant · 2026 · Derived
PubMed: PMID 41728915 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
Pruijm M, Belmar N, Bjornstad P, et al. · Kidney Int · 2026 · Derived
PubMed: PMID 41207620 · NCT04865770 (REMODEL) · Diabetes Mellitus, Type 2
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
Pop-Busui R, Rasmussen S, Deanfield JE, et al. · JAMA Intern Med · 2026 · Derived
PubMed: PMID 41627802 · NCT03914326 (SOUL) · Diabetes Mellitus, Type 2
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.
Nitze LM, Ratziu V, Sanyal AJ, et al. · Aliment Pharmacol Ther · 2026 · Derived
PubMed: PMID 40985232 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
Nicholls SJ, Ryan DH, Deanfield J, et al. · JAMA Cardiol · 2026 · Derived
PubMed: PMID 41433034 · NCT03574597 (SELECT) · Obesity
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
Mulvagh SL, Inzucchi SE, Marx N, et al. · JAMA Cardiol · 2026 · Derived
PubMed: PMID 41879791 · NCT03914326 (SOUL) · Diabetes Mellitus, Type 2
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Meyhöfer SM, Cariou B, Cercato C, et al. · Nat Med · 2026 · Derived
PubMed: PMID 41928037 · NCT03574597 (SELECT) · Obesity
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Mendonça L, Moura H, Chaves PC, et al. · Clin J Am Soc Nephrol · 2026 · Derived
PubMed: PMID 39480988 · NCT03574597 (SELECT) · Obesity
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.
Langer HT, Gilmore NK, Hayden CMT, et al. · Cell Rep Med · 2026 · Derived
PubMed: PMID 41850248 · NCT05606471 (SemVLCD) · Diabetes Mellitus, Type 2
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
Krüger N, Schneeweiss S, Desai RJ, et al. · Nat Med · 2026 · Derived
PubMed: PMID 41207920 · NCT06659744 · Diabetes Mellitus, Type 2
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Klausen MK, Justesen SK, Pedersen JN, et al. · Lancet · 2026 · Derived
PubMed: PMID 42070571 · NCT05895643 (SEMALCO) · Alcoholism
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Heymsfield SB, Aronne LJ, Montgomery P, et al. · Nat Med · 2026 · Derived
PubMed: PMID 41772149 · NCT05616013 · Obesity
A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.
González-Gálvez G, Garnica-Cuellar JC, Colín-García MÁ, et al. · Endocrinol Diabetes Metab · 2026 · Derived
PubMed: PMID 41986942 · NCT04601753 (PIONEER REAL) · Diabetes Mellitus, Type 2
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
Gill H, Badulescu S, Shah H, et al. · JAMA Psychiatry · 2026 · Derived
PubMed: PMID 42054055 · NCT04466345 · Depressive Disorder, Major
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.
Erlandson KM, Kitch DW, Kantor A, et al. · Clin Infect Dis · 2026 · Derived
PubMed: PMID 41299212 · NCT04216589 · Non-alcoholic Fatty Liver Disease
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
Cummings JL, Atri A, Sano M, et al. · Lancet · 2026 · Derived
PubMed: PMID 41865758 · NCT04777409 (EVOKE Plus)
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Cronenberger C, Amin NB, Le VH, et al. · J Clin Pharmacol · 2026 · Derived
PubMed: PMID 42053447 · NCT05671653 · Obesity
Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.
Corley MJ, Pang APS, Kitch DW, et al. · NPJ Aging · 2026 · Derived
PubMed: PMID 42014432 · NCT04216589 · Non-alcoholic Fatty Liver Disease
Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.
Corley M, Pang A, Kitch D, et al. · Res Sq · 2026 · Derived
PubMed: PMID 41256006 · NCT04216589 · Non-alcoholic Fatty Liver Disease
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Boye KS, Thieu VT, Sapin H, et al. · Diabetes Ther · 2026 · Derived
PubMed: PMID 37526908 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye KS, Sapin H, Dong W, et al. · Diabetes Ther · 2026 · Derived
PubMed: PMID 37668888 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Relative Skeletal Muscle Mass Is Associated With Hepatic Steatosis in Adolescents With Overweight and Obesity.
Boster JM, Cree MG, Kelsey MM, et al. · Pediatr Obes · 2026 · Derived
PubMed: PMID 42014131 · NCT03919929 (TEAL) · Non-alcoholic Fatty Liver Disease
Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.
Borlaug BA, Holse C, Jung MH, et al. · JACC Heart Fail · 2026 · Derived
PubMed: PMID 41099689 · NCT03914326 (SOUL) · Diabetes Mellitus, Type 2
Effects of Semaglutide on Cognitive Function in People with HIV: A Randomized Controlled Trial.
Atieh O, Daher J, Abboud M, et al. · Clin Infect Dis · 2026 · Derived
PubMed: PMID 41098140 · NCT04019197 · Obesity
Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
Aronne LJ, Horn DB, Kokkinos AD, et al. · Am J Med · 2026 · Derived
PubMed: PMID 41865857 · NCT05822830 (SURMOUNT-5) · Obesity
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
Szczesnowicz A, Szeliga A, Niwczyk O, et al. · J Clin Med · 2026 · Background
PubMed: PMID 37762856 · NCT07242534 (SEQ) · Obesity
Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.
Sterckx M, De Keyser L · Cureus · 2026 · Background
PubMed: PMID 41773123 · NCT07513168 · Obesity
A high-fat eucaloric diet induces reprometabolic syndrome of obesity in normal weight women.
Santoro N, Kuhn K, Pretzel S, et al. · PNAS Nexus · 2026 · Background
PubMed: PMID 38178979 · NCT06975111

2025 (68 papers)

De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
Rodriguez P, Breslaw N, Xiao H, et al. · Diabetes Obes Metab · 2025 · Trial result
PubMed: PMID 39532398 · NCT04538352 (TRANSITION-T2D) · Diabetes Mellitus, Type 2
Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
Reeder SB, Cruite I, Hamilton G, et al. · J Magn Reson Imaging · 2025 · Trial result
PubMed: PMID 22025886 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
Semaglultide targets Spp1+ microglia/macrophage to attenuate neuroinflammation following perioperative stroke.
Li Y, Fan Q, Pang R, et al. · J Neuroinflammation · 2025 · Trial result
PubMed: PMID 40426210 · NCT07030621 (STARS) · Ischemic Stroke
Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
Yu H, Parker V, Selvarajah V, et al. · Br J Clin Pharmacol · 2025 · Derived
PubMed: PMID 40344607 · NCT04515849 · Diabetes Mellitus, Type 2
A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.
Yammine L, Leidy H, Maki KC, et al. · Contemp Clin Trials · 2025 · Derived
PubMed: PMID 40554081 · NCT06173778 · Obesity
Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.
Xu CL, Kong XC, Liu XM, et al. · Front Endocrinol (Lausanne) · 2025 · Derived
PubMed: PMID 40607222 · NCT05990374 · Diabetes Mellitus
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Wharton S, Lingvay I, Bogdanski P, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40934115 · NCT05564117 (OASIS 4) · Obesity
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
Wharton S, Freitas P, Hjelmesæth J, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
PubMed: PMID 40961952 · NCT05646706 (STEP UP) · Obesity
Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
Wang H, Ko H, Leung TW, et al. · Nat Commun · 2025 · Derived
PubMed: PMID 41392086 · NCT05920889 (GALLOP) · Ischemic Stroke
Pharmacokinetic Characteristics of a Once-Weekly Combination Therapy of Insulin Icodec and Semaglutide Versus Its Separate Components in Chinese Individuals with Type 2 Diabetes.
Wang F, Luan Z, Maltesen R, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 41051695 · NCT05435677 · Diabetes Mellitus, Type 2
Semaglutide in Adults with Type 1 Diabetes and Obesity.
Shah VN, Akturk HK, Kruger D, et al. · NEJM Evid · 2025 · Derived
PubMed: PMID 40550013 · NCT05537233 (ADJUST-T1D) · Obesity
Proteomic signatures reflect effects of semaglutide treatment for MASH.
Schattenberg JM, Grønbæk H, Kliers I, et al. · JHEP Rep · 2025 · Derived
PubMed: PMID 40980163 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India.
Sanyal D, Saboo B, Phatak SR, et al. · Indian J Endocrinol Metab · 2025 · Derived
PubMed: PMID 41229720 · NCT05502562 (PIONEER REAL) · Diabetes Mellitus, Type 2
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Sanyal AJ, Newsome PN, Kliers I, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40305708 · NCT04822181 (ESSENCE) · Non-alcoholic Fatty Liver Disease
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.
Rudofsky G, Amadid H, Braae UC, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 39535683 · NCT04601740 (PIONEER REAL) · Diabetes Mellitus, Type 2
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
Pandey A, Kitzman DW, Chinnakondepalli KM, et al. · JACC Heart Fail · 2025 · Derived
PubMed: PMID 40956259 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants.
Nielsen MS, Brøndsted L, Kankam M, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 39708086 · NCT05227196 · Diabetes Mellitus, Type 2
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
PubMed: PMID 39963952 · NCT04865770 (REMODEL) · Diabetes Mellitus, Type 2
Association of Appendicular Skeletal Muscle Mass Index and Insulin Resistance With Mortality in Multi-Nationwide Cohorts.
Moon S, Choi JW, Park JH, et al. · J Cachexia Sarcopenia Muscle · 2025 · Derived
PubMed: PMID 40230053 · NCT05616013 · Obesity
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
McGuire DK, Marx N, Mulvagh SL, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40162642 · NCT03914326 (SOUL) · Diabetes Mellitus, Type 2
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
McEwan P, Bøg M, Faurby M, et al. · J Med Econ · 2025 · Derived
PubMed: PMID 39882599 · NCT03574597 (SELECT) · Obesity
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Marx N, Deanfield JE, Mann JFE, et al. · Circulation · 2025 · Derived
PubMed: PMID 40156843 · NCT03914326 (SOUL) · Diabetes Mellitus, Type 2
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.
Manti R, De Cosmo S, Desenzani P, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 40128506 · NCT05230615 (PIONEER REAL) · Diabetes Mellitus, Type 2
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial.
Mamas MA, Bays H, Li R, et al. · Eur Heart J Open · 2025 · Derived
PubMed: PMID 40980721 · NCT05822830 (SURMOUNT-5) · Obesity
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
Lübker C, Bhavsar J, Duque do Vale R, et al. · Adv Ther · 2025 · Derived
PubMed: PMID 40156748 · NCT03574597 (SELECT) · Obesity
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
Lingvay I, Bergenheim SJ, Buse JB, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
PubMed: PMID 40961953 · NCT05649137 · Diabetes Mellitus, Type 2
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
Lingvay I, Benamar M, Chen L, et al. · Diabetologia · 2025 · Derived
PubMed: PMID 39820580 · NCT05259033 (COMBINE 2) · Diabetes Mellitus, Type 2
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lim S, Buranapin S, Bao X, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
PubMed: PMID 40825340 · NCT04998136 · Obesity
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease.
Kugathasan L, Aronson Y, Sridhar VS, et al. · Expert Rev Clin Immunol · 2025 · Derived
PubMed: PMID 40693871 · NCT05822609 (RT1D) · Diabetes Mellitus, Type 1
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Krüger N, Schneeweiss S, Fuse K, et al. · JAMA · 2025 · Derived
PubMed: PMID 40886075 · NCT06914102 (DUP-STEP-HFpEF) · Diabetes Mellitus, Type 2
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
Klausen MK, Kuzey T, Pedersen JN, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 39779270 · NCT05895643 (SEMALCO) · Alcoholism
Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.
Kattinakere Sreedhara S, Schneeweiss S, D'Andrea E, et al. · BMJ Open Diabetes Res Care · 2025 · Derived
PubMed: PMID 41161770 · NCT05577728 · Diabetes Mellitus, Type 2
Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.
Katrevula A, Kalapala R, Agrawal S, et al. · Indian J Gastroenterol · 2025 · Derived
PubMed: PMID 41066034 · NCT05442450 (OSO) · Obesity
Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
Kadowaki T, Nishida T, Ogawa W, et al. · Obes Res Clin Pract · 2025 · Derived
PubMed: PMID 40189961 · NCT03811574 (STEP 6) · Obesity
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
Kadowaki T, Heftdal LD, Ko HJ, et al. · JAMA Intern Med · 2025 · Derived
PubMed: PMID 40758358 · NCT05132088 (OASIS 2) · Obesity
Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.
Jensen ME, Klausen MK, Bergmann ML, et al. · Alcohol Clin Exp Res (Hoboken) · 2025 · Derived
PubMed: PMID 40123107 · NCT05895643 (SEMALCO) · Alcoholism
Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.
James S, Christoffersen AD, David JP, et al. · Am Heart J · 2025 · Derived
PubMed: PMID 40345413 · NCT04032197 · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Hendershot CS, Bremmer MP, Paladino MB, et al. · JAMA Psychiatry · 2025 · Derived
PubMed: PMID 39937469 · NCT05520775 · Alcoholism
O-SEMA-FAST: A Prospective, Non-interventional Study Investigating Oral Semaglutide Use in Adults with Type 2 Diabetes Mellitus During Ramadan.
Hassanein M, Alawadi F, AlKadhim I, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 40016571 · NCT05716724 (O-SEMA-Fast) · Diabetes Mellitus, Type 2
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
Gregorič N, Šikonja J, Janež A, et al. · Diabetes Obes Metab · 2025 · Derived
PubMed: PMID 39511836 · NCT06489457 (SEMAT) · Diabetes Mellitus, Type 2
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40544433 · NCT05567796 (REDEFINE 1) · Obesity
Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. · JAMA Psychiatry · 2025 · Derived
PubMed: PMID 40900607 · NCT05193578 (HISTORI) · Overweight
The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.
Funderburg NT, Ross Eckard A, Wu Q, et al. · Open Forum Infect Dis · 2025 · Derived
PubMed: PMID 40160348 · NCT04019197 · Obesity
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.
Freet CS, Shuler K, Kawasaki S, et al. · Res Sq · 2025 · Derived
PubMed: PMID 40502777 · NCT06548490 · Behavior, Addictive
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.
Freet CS, Shuler K, Kawasaki S, et al. · Addict Sci Clin Pract · 2025 · Derived
PubMed: PMID 41168808 · NCT06548490 · Behavior, Addictive
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Ditzenberger GL, Lake JE, Kitch DW, et al. · Clin Infect Dis · 2025 · Derived
PubMed: PMID 39046173 · NCT04216589 · Non-alcoholic Fatty Liver Disease
PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
Delgado Álvarez E, Morales Portillo C, Abreu Padín C, et al. · Diabetes Obes Metab · 2025 · Derived
PubMed: PMID 40555703 · NCT05443334 (PIONEER REAL) · Diabetes Mellitus, Type 2
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Deanfield J, Lincoff AM, Kahn SE, et al. · Lancet · 2025 · Derived
PubMed: PMID 41138739 · NCT03574597 (SELECT) · Obesity
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.
De Block C, Peleshok J, Wilding JPH, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 39531161 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Davies MJ, van der Meer P, Verma S, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
PubMed: PMID 39848268 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ, Bajaj HS, Broholm C, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40544432 · NCT05394519 (REDEFINE 2) · Diabetes Mellitus, Type 2
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Cummings JL, Atri A, Feldman HH, et al. · Alzheimers Res Ther · 2025 · Derived
PubMed: PMID 39780249 · NCT04777396 (EVOKE) · Alzheimer Disease
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.
Buse JB, Nordahl Christensen H, Harty BJ, et al. · BMJ Open Diabetes Res Care · 2025 · Derived
PubMed: PMID 41093600 · NCT03596450 · Diabetes Mellitus, Type 2
Optimizing duodenal tissue acquisition for mechanistic studies of duodenal ablation in type 2 diabetes.
Busch CBE, van den Hoek K, Neefjes-Borst EA, et al. · Endosc Int Open · 2025 · Derived
PubMed: PMID 40007651 · NCT05984238 (EMINENT-2) · Diabetes Mellitus, Type 2
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Borlaug BA, Kitzman DW, Patel S, et al. · JACC Heart Fail · 2025 · Derived
PubMed: PMID 41045908 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
Bonaca MP, Catarig AM, Houlind K, et al. · Lancet · 2025 · Derived
PubMed: PMID 40169145 · NCT04560998 (STRIDE) · Diabetes Mellitus, Type 2
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.
Bain SC, Belmar N, Hoff ST, et al. · Diabetes Ther · 2025 · Derived
PubMed: PMID 39520501 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 40353578 · NCT05822830 (SURMOUNT-5) · Obesity
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Apperloo EM, Gorriz JL, Soler MJ, et al. · Nat Med · 2025 · Derived
PubMed: PMID 39455729 · NCT04889183 (SMART) · Obesity
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes Obes Metab · 2025 · Background
PubMed: PMID 40196933 · NCT07513168 · Obesity
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.
Sundararaman L, Gouda D, Kumar A, et al. · J Clin Med · 2025 · Background
PubMed: PMID 40142784 · NCT07242534 (SEQ) · Obesity
The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation.
Sola-Leyva A, Pathare ADS, Apostolov A, et al. · Acta Obstet Gynecol Scand · 2025 · Background
PubMed: PMID 39696822 · NCT07242534 (SEQ) · Obesity
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA Intern Med · 2025 · Background
PubMed: PMID 38976257 · NCT07513168 · Obesity
Assessing Cardiovascular Risk by Using the Fat Attenuation Index in Coronary CT Angiography.
Klüner LV, Oikonomou EK, Antoniades C, et al. · Radiol Cardiothorac Imaging · 2025 · Background
PubMed: PMID 33778665 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
Kasagga A, Rebellow D, Hashmi T, et al. · Cureus · 2025 · Background
PubMed: PMID 40978842 · NCT07513168 · Obesity
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy.
Johansen VBI, Petersen J, Lund J, et al. · Cell · 2025 · Background
PubMed: PMID 40780185 · NCT07457424 (DIGRAT) · Obesity
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.
Ismaiel A, Scarlata GGM, Boitos I, et al. · Int J Obes (Lond) · 2025 · Background
PubMed: PMID 40804463 · NCT07513168 · Obesity
Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
Hammad MAM, Quesada SG, Belczyk AL, et al. · Toxins (Basel) · 2025 · Background
PubMed: PMID 41295856 · NCT07513168 · Obesity

2024 (71 papers)

A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
Xie P, Abildlund MT, Bækdal TA, et al. · Diabetes Obes Metab · 2024 · Trial result
PubMed: PMID 38808476 · NCT04016974 · Diabetes Mellitus, Type 2
Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.
Westergaard L, Alifrangis L, Buckley ST, et al. · Clin Drug Investig · 2024 · Trial result
PubMed: PMID 39488821 · NCT03789578 · Diabetes Mellitus, Type 2
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.
Suzuki R, Amadid H, Major-Pedersen A, et al. · J Diabetes Investig · 2024 · Trial result
PubMed: PMID 38711208 · NCT04878393 (PIONEER REAL) · Diabetes Mellitus, Type 2
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
Selvarajah V, Robertson D, Hansen L, et al. · Kidney Int · 2024 · Trial result
PubMed: PMID 39218393 · NCT04515849 · Diabetes Mellitus, Type 2
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
Saravanan P, Bell H, Braae UC, et al. · Adv Ther · 2024 · Trial result
PubMed: PMID 39316289 · NCT04862923 (PIONEER REAL) · Diabetes Mellitus, Type 2
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.
Newsome PN, Sanyal AJ, Engebretsen KA, et al. · Aliment Pharmacol Ther · 2024 · Trial result
PubMed: PMID 39412509 · NCT04822181 (ESSENCE) · Non-alcoholic Fatty Liver Disease
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y, Bao X, Eliaschewitz FG, et al. · Lancet Diabetes Endocrinol · 2024 · Trial result
PubMed: PMID 38330988 · NCT04251156 (STEP7) · Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
McGowan BM, Bruun JM, Capehorn M, et al. · Lancet Diabetes Endocrinol · 2024 · Trial result
PubMed: PMID 39089293 · NCT05040971 (STEP 10) · Obesity
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.
Kick A, M'Rabet-Bensalah K, Acquistapace F, et al. · Diabetes Ther · 2024 · Trial result
PubMed: PMID 38240875 · NCT04537624 (PIONEER REAL) · Diabetes Mellitus, Type 2
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.
Gabe MBN, Breitschaft A, Knop FK, et al. · Diabetes Obes Metab · 2024 · Trial result
PubMed: PMID 39082206 · NCT05236517 · Obesity
Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.
Costanzo G, Curatolo S, Busà B, et al. · Endocrinol Diabetes Metab Case Rep · 2024 · Trial result
PubMed: PMID 34463640 · NCT06475586 · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Bliddal H, Bays H, Czernichow S, et al. · N Engl J Med · 2024 · Trial result
PubMed: PMID 39476339 · NCT05064735 · Obesity
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
Wang W, Bain SC, Bian F, et al. · Diabetologia · 2024 · Derived
PubMed: PMID 38985162 · NCT04109547 (PIONEER 11) · Diabetes Mellitus, Type 2
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
Wadden TA, Brown GK, Egebjerg C, et al. · JAMA Intern Med · 2024 · Derived
PubMed: PMID 39226070 · NCT03611582 (STEP 3) · Obesity
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
Verma S, Petrie MC, Borlaug BA, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39217564 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
Verma S, Butler J, Borlaug BA, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39217565 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
Verma S, Butler J, Borlaug BA, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 38913003 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Call for effective therapies for preventing dementia in people with type 2 diabetes.
van Sloten TT, Luchsinger JA, Launer LJ, et al. · Lancet Diabetes Endocrinol · 2024 · Derived
PubMed: PMID 38901446 · NCT04777409 (EVOKE Plus)
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.
van Houtum W, Schrömbges P, Amadid H, et al. · Diabetes Ther · 2024 · Derived
PubMed: PMID 38861137 · NCT04601740 (PIONEER REAL) · Diabetes Mellitus, Type 2
Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.
Sørum ME, Gang AO, Tholstrup DM, et al. · BMJ Open · 2024 · Derived
PubMed: PMID 39384243 · NCT06449625 (PROTECT) · Inflammation
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
Solomon SD, Ostrominski JW, Wang X, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39217567 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Shah SJ, Sharma K, Borlaug BA, et al. · Eur Heart J · 2024 · Derived
PubMed: PMID 38739118 · NCT04788511 (STEP-HFpEF) · Obesity
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Scirica BM, Lincoff AM, Lingvay I, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39217559 · NCT03574597 (SELECT) · Obesity
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Schou M, Petrie MC, Borlaug BA, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 38913004 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Lingvay I, Deanfield J, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38740993 · NCT03574597 (SELECT) · Obesity
Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
Rossing P · J Am Soc Nephrol · 2024 · Derived
PubMed: PMID 39078403 · NCT06082063 (Steno1) · Diabetes Mellitus, Type 1
Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.
Ratziu V, Francque S, Behling CA, et al. · Hepatology · 2024 · Derived
PubMed: PMID 38112484 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Pratley RE, Tuttle KR, Rossing P, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39217553 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, et al. · N Engl J Med · 2024 · Derived
PubMed: PMID 38785209 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Osumili B, Fan L, Paik JS, et al. · Diabetes Res Clin Pract · 2024 · Derived
PubMed: PMID 38777128 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
Natale P, Tunnicliffe DJ, Toyama T, et al. · Cochrane Database Syst Rev · 2024 · Derived
PubMed: PMID 38770818 · NCT04061200 (EmpaSema)
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Mann JFE, Rossing P, Bakris G, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38914124 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.
Lee BW, Cho YM, Kim SG, et al. · Diabetes Ther · 2024 · Derived
PubMed: PMID 38236431 · NCT03061214 (SUSTAIN) · Diabetes Mellitus, Type 2
The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies.
Kral P, Holst-Hansen T, Olivieri AV, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 39316288 · NCT03548935 (STEP 1) · Obesity
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN, Verma S, Borlaug BA, et al. · Circulation · 2024 · Derived
PubMed: PMID 37952180 · NCT04788511 (STEP-HFpEF) · Obesity
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN, Petrie MC, Borlaug BA, et al. · N Engl J Med · 2024 · Derived
PubMed: PMID 38587233 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Kosiborod MN, Deanfield J, Pratley R, et al. · Lancet · 2024 · Derived
PubMed: PMID 39222642 · NCT03574597 (SELECT) · Obesity
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
Ji L, Agesen RM, Bain SC, et al. · Diabetologia · 2024 · Derived
PubMed: PMID 38985161 · NCT04017832 (PIONEER 12) · Diabetes Mellitus, Type 2
Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.
Holmes P, Bell HE, Bozkurt K, et al. · Diabetes Ther · 2024 · Derived
PubMed: PMID 34562237 · NCT03876015 (SURE UK) · Diabetes Mellitus, Type 2
Practical guidelines for eating disorder risk mitigation in patients undergoing obesity treatment for the pediatric provider.
Gordon K, Matthews A, Zeller MH, et al. · Curr Opin Pediatr · 2024 · Derived
PubMed: PMID 38655793 · NCT05548647 (STABLE Wt Loss) · Obesity
Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.
Ganeshalingam AA, Uhrenholt NG, Arnfred S, et al. · BMJ Open · 2024 · Derived
PubMed: PMID 38503415 · NCT05193578 (HISTORI) · Overweight
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.
Eckard AR, Wu Q, Sattar A, et al. · Lancet Diabetes Endocrinol · 2024 · Derived
PubMed: PMID 38964353 · NCT04019197 · Obesity
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.
Dwibedi C, Ekström O, Brandt J, et al. · Nat Metab · 2024 · Derived
PubMed: PMID 38177805 · NCT04451837
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, et al. · Lancet · 2024 · Derived
PubMed: PMID 39181597 · NCT03574597 (SELECT) · Obesity
Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
De La Flor JC, Moral E, Deira J, et al. · Nefrologia (Engl Ed) · 2024 · Derived
PubMed: PMID 38862303 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
Cortes TM, Vasquez L, Serra MC, et al. · JMIR Res Protoc · 2024 · Derived
PubMed: PMID 39269759 · NCT05786521 · Diabetes Mellitus, Type 2
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Lingvay I, Brown PM, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38796653 · NCT03574597 (SELECT) · Obesity
Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
Cirnigliaro CM, La Fountaine MF, Sauer SJ, et al. · J Spinal Cord Med · 2024 · Derived
PubMed: PMID 37158751 · NCT03292315 · Obesity
PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice.
Catrina SB, Amadid H, Braae UC, et al. · Diabetes Ther · 2024 · Derived
PubMed: PMID 39052163 · NCT04601753 (PIONEER REAL) · Diabetes Mellitus, Type 2
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J, Shah SJ, Petrie MC, et al. · Lancet · 2024 · Derived
PubMed: PMID 38599221 · NCT04788511 (STEP-HFpEF) · Obesity
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Derived
PubMed: PMID 38095657 · NCT04153929 · Diabetes Mellitus, Type 2
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, Bilal A, Lee MMY, et al. · Lancet Diabetes Endocrinol · 2024 · Derived
PubMed: PMID 39608381 · NCT03574597 (SELECT) · Obesity
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
Al-Ozairi E, Narula K, Miras AD, et al. · Trials · 2024 · Derived
PubMed: PMID 38365744 · NCT05390307 (OTID) · Obesity
Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
Ahmed A, Monir Akl M · Adv Pharm Bull · 2024 · Derived
PubMed: PMID 39206389 · NCT06057077 · Diabetes Mellitus, Type 1
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.
Williams SM, Eleftheriadou A, Alam U, et al. · Diabetes Ther · 2024 · Background
PubMed: PMID 31552598 · NCT06461377 · Diabetes Mellitus, Type 2
Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature.
Pavli P, Triantafyllidou O, Kapantais E, et al. · Int J Mol Sci · 2024 · Background
PubMed: PMID 38339186 · NCT07242534 (SEQ) · Obesity
The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis.
Patel D, Ayesha IE, Monson NR, et al. · Cureus · 2024 · Background
PubMed: PMID 37900422 · NCT06975111
Pharmacologic Treatment of Obesity in Reproductive Aged Women.
Nuako A, Tu L, Reyes KJC, et al. · Curr Obstet Gynecol Rep · 2024 · Background
PubMed: PMID 37427372 · NCT07242534 (SEQ) · Obesity
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Moiz A, Levett JY, Filion KB, et al. · Am J Cardiol · 2024 · Background
PubMed: PMID 38679221 · NCT07513168 · Obesity
Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
Kobayati A, Haidar A, Tsoukas MA, et al. · Diabetes Obes Metab · 2024 · Background
PubMed: PMID 34989070 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).
Kalra S, Bhattacharya S, Kapoor N, et al. · Diabetes Ther · 2024 · Background
PubMed: PMID 34268675 · NCT06154486 · Pneumonia, Aspiration
Vasomotor Symptom Trajectories and Risk of Incident Diabetes.
Hedderson MM, Liu EF, Lee C, et al. · JAMA Netw Open · 2024 · Background
PubMed: PMID 39480425 · NCT06975111
Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists.
Goldberg AS, Boots CE · Fertil Steril · 2024 · Background
PubMed: PMID 38810863 · NCT07242534 (SEQ) · Obesity
Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review.
Goh JK, Koh L · Diabetol Int · 2024 · Background
PubMed: PMID 37397902 · NCT06461377 · Diabetes Mellitus, Type 2
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
Evans M, Morgan AR, Bain SC, et al. · Diabetes Ther · 2024 · Background
PubMed: PMID 35044569 · NCT07043361 (Semaglutide) · Metabolic Diseases
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), et al. · J Hepatol · 2024 · Background
PubMed: PMID 38851997 · NCT07513168 · Obesity
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptide-1 Receptor Agonists · 2024 · Background
PubMed: PMID 31855395 · NCT06363487 (OxSENSE)
An explanation for the accuracy of sensor-based measures of energy intake: Amount of food consumed matters more than dietary composition.
Chou T, Hoover AW, Goldstein SP, et al. · Appetite · 2024 · Background
PubMed: PMID 38154576 · NCT07457424 (DIGRAT) · Obesity
Eating disorders and obesity: bridging clinical, neurobiological, and therapeutic perspectives.
Camacho-Barcia L, Giel KE, Jiménez-Murcia S, et al. · Trends Mol Med · 2024 · Background
PubMed: PMID 38485648 · NCT07457424 (DIGRAT) · Obesity
A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design.
BenAri O, Efrati S, Sano M, et al. · Alzheimers Dement (N Y) · 2024 · Background
PubMed: PMID 32296731 · NCT06072963 · Metabolic Syndrome
A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
Bader S, Bhatti R, Mussa B, et al. · Womens Health (Lond) · 2024 · Background
PubMed: PMID 38444070 · NCT07242534 (SEQ) · Obesity

2023 (57 papers)

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. · Adv Ther · 2023 · Trial result
PubMed: PMID 36542260 · NCT03929679 (SURE NL) · Diabetes Mellitus, Type 2
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M, Lawitz E, Shankar RR, et al. · J Hepatol · 2023 · Trial result
PubMed: PMID 37355043 · NCT04944992 · Non-alcoholic Fatty Liver Disease
Clinically Ineffective Reperfusion After Endovascular Therapy in Acute Ischemic Stroke.
Nie X, Leng X, Miao Z, et al. · Stroke · 2023 · Trial result
PubMed: PMID 36475464 · NCT07030621 (STARS) · Ischemic Stroke
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · N Engl J Med · 2023 · Trial result
PubMed: PMID 37952131 · NCT03574597 (SELECT) · Obesity
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · N Engl J Med · 2023 · Trial result
PubMed: PMID 37622681 · NCT04788511 (STEP-HFpEF) · Obesity
Effects of GLP-1 receptor agonists on neurological complications of diabetes.
García-Casares N, González-González G, de la Cruz-Cosme C, et al. · Rev Endocr Metab Disord · 2023 · Trial result
PubMed: PMID 37231200 · NCT07030621 (STARS) · Ischemic Stroke
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Aroda VR, Aberle J, Bardtrum L, et al. · Lancet · 2023 · Trial result
PubMed: PMID 37385279 · NCT04707469 (PIONEER PLUS) · Diabetes Mellitus, Type 2
Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.
Wilkinson L, Holst-Hansen T, Laursen PN, et al. · Obesity (Silver Spring) · 2023 · Derived
PubMed: PMID 37605636 · NCT03693430 (STEP 5) · Obesity
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
Weghuber D, Boberg K, Hesse D, et al. · J Comp Eff Res · 2023 · Derived
PubMed: PMID 36534451 · NCT04102189 · Obesity
FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial.
Wai-Sun Wong V, Anstee QM, Nitze LM, et al. · EClinicalMedicine · 2023 · Derived
PubMed: PMID 38058795 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
Viljoen A, Pantalone KM, Galindo RJ, et al. · Diabetes Ther · 2023 · Derived
PubMed: PMID 37000390 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.
van Hout M, Forte P, Jensen TB, et al. · Clin Pharmacokinet · 2023 · Derived
PubMed: PMID 36932262 · NCT04513704
Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
Taylor SI, Montasser ME, Yuen AH, et al. · Diabetes Obes Metab · 2023 · Derived
PubMed: PMID 37264484 · NCT05071898 (PORT) · Diabetes Mellitus, Type 2
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR, Danielsen AA, Köhler-Forsberg O, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 36720576 · NCT04892199 · Diabetes Mellitus, Type 2
Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
Rowe IA, Allen AM · Hepatology · 2023 · Derived
PubMed: PMID 36738088 · NCT04822181 (ESSENCE) · Non-alcoholic Fatty Liver Disease
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Rossing P, Bain SC, Bosch-Traberg H, et al. · Cardiovasc Diabetol · 2023 · Derived
PubMed: PMID 37620807 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.
Romero-Gómez M, Armstrong MJ, Funuyet-Salas J, et al. · Aliment Pharmacol Ther · 2023 · Derived
PubMed: PMID 37328931 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren H, Berry S, Malkin SJP, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 37775297 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
Reitzel SB, Bøgelund M, Basse A, et al. · Curr Med Res Opin · 2023 · Derived
PubMed: PMID 37415503 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
Pulleyblank R, Larsen NB · Pharmacoecon Open · 2023 · Derived
PubMed: PMID 37178435 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.
McGowan BM, Houshmand-Oeregaard A, Laursen PN, et al. · Obesity (Silver Spring) · 2023 · Derived
PubMed: PMID 36876594 · NCT03548935 (STEP 1) · Obesity
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Kosiborod MN, Bhatta M, Davies M, et al. · Diabetes Obes Metab · 2023 · Derived
PubMed: PMID 36200477 · NCT03548935 (STEP 1) · Obesity
Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.
Kelly AS, Arslanian S, Hesse D, et al. · Obesity (Silver Spring) · 2023 · Derived
PubMed: PMID 37196421 · NCT04102189 · Obesity
Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.
Ingersen A, Schmücker M, Alexandersen C, et al. · J Clin Endocrinol Metab · 2023 · Derived
PubMed: PMID 37265222 · NCT04383197 (EXISECRET) · Diabetes Mellitus, Type 2
Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.
Helsted MM, Gasbjerg LS, Vilsbøll T, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 36849212 · NCT05078255 · Diabetes Mellitus, Type 2
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Heise T, DeVries JH, Urva S, et al. · Diabetes Care · 2023 · Derived
PubMed: PMID 36857477 · NCT03951753 · Diabetes Mellitus, Type 2
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
Heerspink HJL, Apperloo E, Davies M, et al. · Diabetes Care · 2023 · Derived
PubMed: PMID 36801984 · NCT03552757 (STEP 2) · Obesity
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
Butler J, Abildstrøm SZ, Borlaug BA, et al. · J Am Coll Cardiol · 2023 · Derived
PubMed: PMID 37993201 · NCT04788511 (STEP-HFpEF) · Obesity
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.
Buse JB, Nordahl Christensen H, Harty BJ, et al. · BMJ Open Diabetes Res Care · 2023 · Derived
PubMed: PMID 37137527 · NCT03596450 · Diabetes Mellitus, Type 2
Design, analysis, and interpretation of treatment response heterogeneity in personalized nutrition and obesity treatment research.
Zoh RS, Esteves BH, Yu X, et al. · Obes Rev · 2023 · Background
PubMed: PMID 37667550 · NCT07457424 (DIGRAT) · Obesity
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Wharton S, Batterham RL, Bhatta M, et al. · Obesity (Silver Spring) · 2023 · Background
PubMed: PMID 36655300 · NCT03693430 (STEP 5) · Obesity
Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T, Lindahl CØ, Nielsen NF, et al. · Diabetes Obes Metab · 2023 · Background
PubMed: PMID 36809678 · NCT04261933 (SURE GERMANY) · Diabetes Mellitus, Type 2
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Tsoukas MA, Woo V, Tobe SW, et al. · Diabetes Obes Metab · 2023 · Background
PubMed: PMID 36942888 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, et al. · Diabetes Obes Metab · 2023 · Background
PubMed: PMID 36722623 · NCT06243536 · Diabetes Mellitus, Type 2
Burst-pause criterion derivation for drinkometer measurements of ingestive behavior.
Serra M, File B, Alceste D, et al. · MethodsX · 2023 · Background
PubMed: PMID 35620756 · NCT07457424 (DIGRAT) · Obesity
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, et al. · Nephrol Dial Transplant · 2023 · Background
PubMed: PMID 36651820 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
Quddos F, Hubshman Z, Tegge A, et al. · Sci Rep · 2023 · Background
PubMed: PMID 38017205 · NCT07513168 · Obesity
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, et al. · Am Heart J · 2023 · Background
PubMed: PMID 37758044 · NCT06779929 · Diabetes Mellitus, Type 2
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Napoli R, Berra C, Catarig AM, et al. · Diabetes Obes Metab · 2023 · Background
PubMed: PMID 36789682 · NCT04094415 (SURE ITALY) · Diabetes Mellitus, Type 2
Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
Mohammedi K, Belhatem N, Berentzen TL, et al. · Diabetes Obes Metab · 2023 · Background
PubMed: PMID 36869853 · NCT04083820 (SURE FRANCE) · Diabetes Mellitus, Type 2
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.
Marx N, Federici M, Schütt K, et al. · Eur Heart J · 2023 · Background
PubMed: PMID 37622663 · NCT07314684 (STABLE-GLP1) · Diabetes Mellitus, Type 2
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R, Abdelmalek MF, Armstrong MJ, et al. · Lancet Gastroenterol Hepatol · 2023 · Background
PubMed: PMID 36934740 · NCT03987451 · Non-alcoholic Fatty Liver Disease
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
Li A, Su X, Hu S, et al. · Diabetes Res Clin Pract · 2023 · Background
PubMed: PMID 36871874 · NCT06072963 · Metabolic Syndrome
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · JACC Heart Fail · 2023 · Background
PubMed: PMID 37294245 · NCT04916470 (STEP HFpEF DM) · Diabetes Mellitus
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Knop FK, Aroda VR, do Vale RD, et al. · Lancet · 2023 · Background
PubMed: PMID 37385278 · NCT05035095 (OASIS 1) · Obesity
Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice.
Khan D, Ojo OO, Woodward OR, et al. · Biomolecules · 2023 · Background
PubMed: PMID 36551163 · NCT07242534 (SEQ) · Obesity
Cardiac autonomic dysfunction and risk of incident stroke among adults with type 2 diabetes.
Kaze AD, Yuyun MF, Fonarow GC, et al. · Eur Stroke J · 2023 · Background
PubMed: PMID 37021204 · NCT06461377 · Diabetes Mellitus, Type 2
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Johansen P, Håkan-Bloch J, Liu AR, et al. · Pharmacoecon Open · 2023 · Background
PubMed: PMID 30927241 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Pramipexole Enhances Reward Learning by Preserving Value Estimates.
Halahakoon DC, Kaltenboeck A, Martens M, et al. · Biol Psychiatry · 2023 · Background
PubMed: PMID 37330165 · NCT06363487 (OxSENSE)
The challenges of obesity for fertility: A FIGO literature review.
Gautam D, Purandare N, Maxwell CV, et al. · Int J Gynaecol Obstet · 2023 · Background
PubMed: PMID 36635080 · NCT07242534 (SEQ) · Obesity
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP, Deenadayalan S, Erichsen L, et al. · Lancet · 2023 · Background
PubMed: PMID 37364590 · NCT04982575 · Diabetes Mellitus, Type 2
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide.
Fonseca VA, Capehorn MS, Garg SK, et al. · J Clin Endocrinol Metab · 2023 · Background
PubMed: PMID 30938762 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Tsagarakis S, Terzolo M, et al. · Eur J Endocrinol · 2023 · Background
PubMed: PMID 37318239 · NCT07361874 (IMPACT-MACS) · Weight Loss
Obesity Management in Adults: A Review.
Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. · JAMA · 2023 · Background
PubMed: PMID 38015216 · NCT07513168 · Obesity
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
Chuong V, Farokhnia M, Khom S, et al. · JCI Insight · 2023 · Background
PubMed: PMID 37192005 · NCT06015893 · Alcoholism
Semaglutide for the treatment of obesity.
Chao AM, Tronieri JS, Amaro A, et al. · Trends Cardiovasc Med · 2023 · Background
PubMed: PMID 34942372 · NCT07513168 · Obesity
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA, Kitzman DW, Davies MJ, et al. · Nat Med · 2023 · Background
PubMed: PMID 37635157 · NCT04788511 (STEP-HFpEF) · Obesity

2022 (87 papers)

Endovascular Therapy for Acute Stroke with a Large Ischemic Region.
Yoshimura S, Sakai N, Yamagami H, et al. · N Engl J Med · 2022 · Trial result
PubMed: PMID 35138767 · NCT07030621 (STARS) · Ischemic Stroke
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
Xing C, Zhao H, Zhang J, et al. · Front Endocrinol (Lausanne) · 2022 · Trial result
PubMed: PMID 36060969 · NCT05702905 · Obesity
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Wharton S, Davies M, Dicker D, et al. · Postgrad Med · 2022 · Trial result
PubMed: PMID 34775881 · NCT04074161 (STEP 8) · Obesity
Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. · N Engl J Med · 2022 · Trial result
PubMed: PMID 36322838 · NCT04102189 · Obesity
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022 · Trial result
PubMed: PMID 35015037 · NCT04074161 (STEP 8) · Obesity
GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons.
Papaetis GS, Kyriacou A · Adv Clin Exp Med · 2022 · Trial result
PubMed: PMID 35951627 · NCT05702905 · Obesity
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Li R, Mai T, Zheng S, et al. · Arch Gynecol Obstet · 2022 · Trial result
PubMed: PMID 35829765 · NCT05702905 · Obesity
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M, Kaltoft MS, Lawson J, et al. · Diabetes Obes Metab · 2022 · Trial result
PubMed: PMID 35546450 · NCT03689374 (SUSTAIN 11) · Diabetes Mellitus, Type 2
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Husain M, Consoli A, De Remigis A, et al. · Cardiovasc Diabetol · 2022 · Trial result
PubMed: PMID 35484580 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery.
Hess DA, Trac JZ, Glazer SA, et al. · Cell Rep Med · 2022 · Trial result
PubMed: PMID 33205058 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Fast tipping point sensitivity analyses in clinical trials with missing continuous outcomes under multiple imputation.
Gorst-Rasmussen A, Tarp-Johansen MJ · J Biopharm Stat · 2022 · Trial result
PubMed: PMID 35653556 · NCT02906930 (PIONEER 1) · Diabetes Mellitus, Type 2
The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
Ge JJ, Wang DJ, Song W, et al. · J Endocrinol Invest · 2022 · Trial result
PubMed: PMID 34455568 · NCT05702905 · Obesity
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
Evans LM, Mellbin L, Johansen P, et al. · Endocrinol Diabetes Metab · 2022 · Trial result
PubMed: PMID 34277983 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Eliasson B, Ericsson Å, Fridhammar A, et al. · Pharmacoecon Open · 2022 · Trial result
PubMed: PMID 35064550 · NCT02607865 (PIONEER 3) · Diabetes Mellitus, Type 2
Inflammatory Responses After Ischemic Stroke.
DeLong JH, Ohashi SN, O'Connor KC, et al. · Semin Immunopathol · 2022 · Trial result
PubMed: PMID 35767089 · NCT07030621 (STARS) · Ischemic Stroke
The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.
Cui QN, Stein LM, Fortin SM, et al. · Br J Pharmacol · 2022 · Trial result
PubMed: PMID 34519040 · NCT07030621 (STARS) · Ischemic Stroke
Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities.
Candelario-Jalil E, Dijkhuizen RM, Magnus T, et al. · Stroke · 2022 · Trial result
PubMed: PMID 35387495 · NCT07030621 (STARS) · Ischemic Stroke
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Aroda VR, Bauer R, Christiansen E, et al. · Diabetes Obes Metab · 2022 · Trial result
PubMed: PMID 35373893 · NCT02849080 (PIONEER 7) · Diabetes Mellitus, Type 2
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, et al. · J Hepatol · 2022 · Trial result
PubMed: PMID 35439567 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF, Bodholdt U, Catarig AM, et al. · BMJ Open Diabetes Res Care · 2022 · Derived
PubMed: PMID 35383100 · NCT03648281 · Diabetes Mellitus, Type 2
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35441470 · NCT03548935 (STEP 1) · Obesity
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S, Al-Omran M, Leiter LA, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35332654 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial.
Ten Doesschate T, van der Vaart TW, Debisarun PA, et al. · Clin Microbiol Infect · 2022 · Derived
PubMed: PMID 35489606 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
Strain WD, Frenkel O, James MA, et al. · Stroke · 2022 · Derived
PubMed: PMID 35582947 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
Snitker S, Egebjerg C, Frederiksen M, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35791625 · NCT04074161 (STEP 8) · Obesity
Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
Snitker S, Andersen A, Lindskov PS, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35434913 · NCT04007107
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Sattar N, McGuire DK, Pavo I, et al. · Nat Med · 2022 · Derived
PubMed: PMID 35210595 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
Perreault L, Davies M, Frias JP, et al. · Diabetes Care · 2022 · Derived
PubMed: PMID 35724304 · NCT03611582 (STEP 3) · Obesity
An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT).
O'Sullivan L, Savinelli S, O'Hare S, et al. · Trials · 2022 · Derived
PubMed: PMID 35039057 · NCT04174755 (SWIFT) · Obesity
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
Mosenzon O, Capehorn MS, De Remigis A, et al. · Cardiovasc Diabetol · 2022 · Derived
PubMed: PMID 36056351 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
Mares AC, Chatterjee S, Mukherjee D, et al. · Curr Opin Cardiol · 2022 · Derived
PubMed: PMID 35175229 · NCT03574597 (SELECT) · Obesity
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Leite AR, Angélico-Gonçalves A, Vasques-Nóvoa F, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35373878 · NCT03574597 (SELECT) · Obesity
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T, Isendahl J, Khalid U, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
PubMed: PMID 35131037 · NCT03811574 (STEP 6) · Obesity
Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).
Janić M, Rizzo M, Cosentino F, et al. · Diabetes Ther · 2022 · Derived
PubMed: PMID 35258841 · NCT05147896 (SAMAS) · Diabetes Mellitus, Type 2
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, Mari A, DeVries JH, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
PubMed: PMID 35468322 · NCT03951753 · Diabetes Mellitus, Type 2
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, Batterham RL, Bhatta M, et al. · Nat Med · 2022 · Derived
PubMed: PMID 36216945 · NCT03693430 (STEP 5) · Obesity
Progress in pediatric obesity: new and advanced therapies.
Cuda S, Censani M · Curr Opin Pediatr · 2022 · Derived
PubMed: PMID 35797460 · NCT04102189 · Obesity
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Cohen S, Sternlicht H, Bakris GL, et al. · Curr Diab Rep · 2022 · Derived
PubMed: PMID 35441935 · NCT03819153 (FLOW) · Diabetes Mellitus, Type 2
Effect of Metabolic Syndrome on the Incidence of Dementia Based on National Insurance Data in Korea.
Yoo H, Kim H, Koh I, et al. · Metab Syndr Relat Disord · 2022 · Background
PubMed: PMID 34756135 · NCT06072963 · Metabolic Syndrome
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.
Yesildag B, Mir-Coll J, Neelakandhan A, et al. · Clin Immunol · 2022 · Background
PubMed: PMID 36084852 · NCT07430332 · Diabetes Mellitus, Type 1
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.
Yabe D, Yamada Y, Kaku K, et al. · J Diabetes Investig · 2022 · Background
PubMed: PMID 35174649 · NCT07043361 (Semaglutide) · Metabolic Diseases
The physiological control of eating: signals, neurons, and networks.
Watts AG, Kanoski SE, Sanchez-Watts G, et al. · Physiol Rev · 2022 · Background
PubMed: PMID 34486393 · NCT06243536 · Diabetes Mellitus, Type 2
Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
Wabitsch M, Farooqi S, Flück CE, et al. · J Endocr Soc · 2022 · Background
PubMed: PMID 35528826 · NCT07302802
The Partitioning of Newly Assimilated Linoleic and α-Linolenic Acids Between Synthesis of Longer-Chain Polyunsaturated Fatty Acids and Hydroxyoctadecaenoic Acids Is a Putative Branch Point in T-Cell Essential Fatty Acid Metabolism.
von Gerichten J, West AL, Irvine NA, et al. · Front Immunol · 2022 · Background
PubMed: PMID 34675928 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.
Valerio CM, de Almeida JS, Moreira RO, et al. · Diabetol Metab Syndr · 2022 · Background
PubMed: PMID 28450900 · NCT06827002 · Obesity
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.
Tommerdahl KL, Nadeau KJ, Bjornstad P, et al. · Adv Chronic Kidney Dis · 2022 · Background
PubMed: PMID 34922690 · NCT06243536 · Diabetes Mellitus, Type 2
Early Postoperative Weight Loss Predicts Weight Loss up to 5 Years After Roux-En-Y Gastric Bypass, Banded Roux-En-Y Gastric Bypass, and Sleeve Gastrectomy.
Tettero OM, Monpellier VM, Janssen IMC, et al. · Obes Surg · 2022 · Background
PubMed: PMID 35842505 · NCT06287307 (SEABAR) · Obesity
Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples.
Terenzi DC, Bakbak E, Trac JZ, et al. · STAR Protoc · 2022 · Background
PubMed: PMID 33554145 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM, et al. · J ASEAN Fed Endocr Soc · 2022 · Background
PubMed: PMID 36578889 · NCT07513168 · Obesity
The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Stafeev I, Sorkina E, Koksharova E, et al. · Curr Mol Med · 2022 · Background
PubMed: PMID 33261539 · NCT05419726 · Obesity
Safety of Semaglutide.
Smits MM, Van Raalte DH · Front Endocrinol (Lausanne) · 2022 · Background
PubMed: PMID 34305810 · NCT06072963 · Metabolic Syndrome
Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, Krauthamer M, Bjalme-Evans M, et al. · J Investig Med · 2022 · Background
PubMed: PMID 34706925 · NCT07513168 · Obesity
Epigenetic age prediction.
Simpson DJ, Chandra T · Aging Cell · 2022 · Background
PubMed: PMID 34415665 · NCT06975111
Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations.
Shu MJ, Zhai FF, Zhang DD, et al. · Stroke Vasc Neurol · 2022 · Background
PubMed: PMID 33903177 · NCT06072963 · Metabolic Syndrome
Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S, Kunutsor SK, Topsever P, et al. · Endocrinol Diabetes Metab · 2022 · Background
PubMed: PMID 34636161 · NCT06072963 · Metabolic Syndrome
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers.
Rózga M, Bittner T, Batrla R, et al. · Alzheimers Dement (Amst) · 2022 · Background
PubMed: PMID 30984815 · NCT06072963 · Metabolic Syndrome
Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.
Prete A, Subramanian A, Bancos I, et al. · Ann Intern Med · 2022 · Background
PubMed: PMID 34978855 · NCT07361874 (IMPACT-MACS) · Weight Loss
Glucose variability: A physiological correlate of eating disorder behaviors among individuals with binge-spectrum eating disorders.
Presseller EK, Patarinski AGG, Zhang F, et al. · Int J Eat Disord · 2022 · Background
PubMed: PMID 36305323 · NCT06243536 · Diabetes Mellitus, Type 2
Deglutition and the Regulation of the Swallow Motor Pattern.
Pitts T, Iceman KE · Physiology (Bethesda) · 2022 · Background
PubMed: PMID 35998250 · NCT07457424 (DIGRAT) · Obesity
Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.
Pasqua MR, Jafar A, Kobayati A, et al. · Diabetes Care · 2022 · Background
PubMed: PMID 36331522 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Does binge-eating matter for glycemic control in type 2 diabetes patients?
Papelbaum M, de Oliveira Moreira R, Coutinho WF, et al. · J Eat Disord · 2022 · Background
PubMed: PMID 31516703 · NCT06243536 · Diabetes Mellitus, Type 2
Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.
Oliveira FCB, Bauer EJ, Ribeiro CM, et al. · Front Endocrinol (Lausanne) · 2022 · Background
PubMed: PMID 35069450 · NCT05419726 · Obesity
MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
Novak V, Mantzoros CS, Novak P, et al. · J Neurol · 2022 · Background
PubMed: PMID 35482079 · NCT06072963 · Metabolic Syndrome
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ · Front Endocrinol (Lausanne) · 2022 · Background
PubMed: PMID 34248838 · NCT06243536 · Diabetes Mellitus, Type 2
Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.
Marty VN, Farokhnia M, Munier JJ, et al. · Front Neurosci · 2022 · Background
PubMed: PMID 33424537 · NCT06015893 · Alcoholism
Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial.
Legro RS, Hansen KR, Diamond MP, et al. · PLoS Med · 2022 · Background
PubMed: PMID 35041662 · NCT06975111
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.
Klausen MK, Thomsen M, Wortwein G, et al. · Br J Pharmacol · 2022 · Background
PubMed: PMID 34532853 · NCT06015893 · Alcoholism
The Universal Eating Monitor (UEM): objective assessment of food intake behavior in the laboratory setting.
Kissileff HR · Int J Obes (Lond) · 2022 · Background
PubMed: PMID 35233038 · NCT07457424 (DIGRAT) · Obesity
Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial.
Kellar D, Register T, Lockhart SN, et al. · Sci Rep · 2022 · Background
PubMed: PMID 35079029 · NCT06072963 · Metabolic Syndrome
Hormones and bone loss across the menopause transition.
Karlamangla AS, Shieh A, Greendale GA, et al. · Vitam Horm · 2022 · Background
PubMed: PMID 33706956 · NCT06975111
Oral Semaglutide: Dosage in Special Situations.
Kalra S, Kapoor N · Diabetes Ther · 2022 · Background
PubMed: PMID 35532859 · NCT07043361 (Semaglutide) · Metabolic Diseases
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Jensen SBK, Janus C, Lundgren JR, et al. · Nat Commun · 2022 · Background
PubMed: PMID 35970829 · NCT05574439 (RESETTLE) · Weight Loss
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.
Iepsen EW, Have CT, Veedfald S, et al. · Cell Rep Med · 2022 · Background
PubMed: PMID 33205056 · NCT07302802
Epicardial adipose tissue in contemporary cardiology.
Iacobellis G · Nat Rev Cardiol · 2022 · Background
PubMed: PMID 35296869 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Vascular repair and regeneration in cardiometabolic diseases.
Hess DA, Verma S, Bhatt D, et al. · Eur Heart J · 2022 · Background
PubMed: PMID 34849704 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
Haidar A, Lovblom LE, Cardinez N, et al. · Nat Med · 2022 · Background
PubMed: PMID 35551290 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Microstructural changes in human ingestive behavior after Roux-en-Y gastric bypass during liquid meals.
Gero D, File B, Alceste D, et al. · JCI Insight · 2022 · Background
PubMed: PMID 34369388 · NCT07457424 (DIGRAT) · Obesity
Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use.
Farokhnia M, Fede SJ, Grodin EN, et al. · Sci Rep · 2022 · Background
PubMed: PMID 35906358 · NCT06015893 · Alcoholism
The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.
Farokhnia M, Browning BD, Crozier ME, et al. · Addict Biol · 2022 · Background
PubMed: PMID 36001436 · NCT06015893 · Alcoholism
Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial.
Doniger GM, Beeri MS, Bahar-Fuchs A, et al. · Alzheimers Dement (N Y) · 2022 · Background
PubMed: PMID 29955655 · NCT06072963 · Metabolic Syndrome
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.
Detka J, Głombik K · Pharmacol Rep · 2022 · Background
PubMed: PMID 34003475 · NCT06363487 (OxSENSE)
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, Aroda VR, Collins BS, et al. · Diabetologia · 2022 · Background
PubMed: PMID 36151309 · NCT07043361 (Semaglutide) · Metabolic Diseases
Cumulative Exposure to Metabolic Syndrome Components and the Risk of Dementia: A Nationwide Population-Based Study.
Cho Y, Han K, Kim DH, et al. · Endocrinol Metab (Seoul) · 2022 · Background
PubMed: PMID 33849249 · NCT06072963 · Metabolic Syndrome
Semaglutide for the treatment of overweight and obesity: A review.
Bergmann NC, Davies MJ, Lingvay I, et al. · Diabetes Obes Metab · 2022 · Background
PubMed: PMID 36254579 · NCT07513168 · Obesity
Potential Adverse Effects of Female and Male Obesity on Fertility: A Narrative Review.
Amiri M, Ramezani Tehrani F · Int J Endocrinol Metab · 2022 · Background
PubMed: PMID 33257906 · NCT07242534 (SEQ) · Obesity
Association between microstructure of ingestive behavior and body weight loss in patients one year after Roux-en-Y gastric bypass.
Alceste D, Serra M, Raguz I, et al. · Physiol Behav · 2022 · Background
PubMed: PMID 35134394 · NCT07457424 (DIGRAT) · Obesity
The 2022 hormone therapy position statement of The North American Menopause Society.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel · Menopause · 2022 · Background
PubMed: PMID 35797481 · NCT06975111

2021 (94 papers)

Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
Yale JF, Catarig AM, Grau K, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 34142429 · NCT03457012 (SURE CANADA) · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med · 2021 · Trial result
PubMed: PMID 33567185 · NCT03574597 (SELECT) · Obesity
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Trial result
PubMed: PMID 33625476 · NCT03611582 (STEP 3) · Obesity
Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
Snitker S, Andersen A, Berg B, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 33591618 · NCT04189848 · Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Shi A, Xie P, Nielsen LL, et al. · Adv Ther · 2021 · Trial result
PubMed: PMID 33159658 · NCT03288740 · Diabetes Mellitus, Type 2
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N, Lee MMY, Kristensen SL, et al. · Lancet Diabetes Endocrinol · 2021 · Trial result
PubMed: PMID 34425083 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
Rudofsky G, Catarig AM, Favre L, et al. · Diabetes Res Clin Pract · 2021 · Trial result
PubMed: PMID 34217773 · NCT03631186 · Diabetes Mellitus, Type 2
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Trial result
PubMed: PMID 33755728 · NCT03548987 (STEP 4) · Obesity
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. · Prim Care Diabetes · 2021 · Trial result
PubMed: PMID 34183269 · NCT03648281 · Diabetes Mellitus, Type 2
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, et al. · N Engl J Med · 2021 · Trial result
PubMed: PMID 33185364 · NCT02970942 · Non-alcoholic Fatty Liver Disease
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA, Quast DR, Wefers J, et al. · Mol Metab · 2021 · Trial result
PubMed: PMID 33068776 · NCT06475586 · Diabetes Mellitus, Type 2
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
McCrimmon RJ, Catarig AM, Frias JP, et al. · Diabetologia · 2021 · Trial result
PubMed: PMID 31897524 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Ma RL, Deng Y, Wang YF, et al. · Chin Med J (Engl) · 2021 · Trial result
PubMed: PMID 34732660 · NCT05702905 · Obesity
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 33074557 · NCT03061214 (SUSTAIN) · Diabetes Mellitus, Type 2
Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
Ishii H, Hansen BB, Langer J, et al. · Diabetes Ther · 2021 · Trial result
PubMed: PMID 33460016 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
Gibbons C, Blundell J, Tetens Hoff S, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 33184979 · NCT02773381 · Diabetes Mellitus, Type 2
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Stroke Collaborators · Lancet Neurol · 2021 · Trial result
PubMed: PMID 34487721 · NCT07030621 (STARS) · Ischemic Stroke
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 33269530 · NCT03842202 · Obesity
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, et al. · Lancet Diabetes Endocrinol · 2021 · Trial result
PubMed: PMID 34293304 · NCT03989232 (SUSTAIN FORTE) · Diabetes Mellitus, Type 2
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
Flint A, Andersen G, Hockings P, et al. · Aliment Pharmacol Ther · 2021 · Trial result
PubMed: PMID 34570916 · NCT03357380 · Non-alcoholic Fatty Liver Disease
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB, Berthelsen KK, Kankam M, et al. · Lancet · 2021 · Trial result
PubMed: PMID 33894838 · NCT03600480 · Obesity
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, et al. · Lancet · 2021 · Trial result
PubMed: PMID 33667417 · NCT03811574 (STEP 6) · Obesity
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H, Chiovato L, Nappi RE, et al. · J Clin Endocrinol Metab · 2021 · Trial result
PubMed: PMID 32442310 · NCT05702905 · Obesity
Diabetes mellitus impairs circulating proangiogenic granulocytes.
Cappellari R, D'Anna M, Menegazzo L, et al. · Diabetologia · 2021 · Trial result
PubMed: PMID 32306097 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS, Catarig AM, Furberg JK, et al. · Diabetes Metab · 2021 · Trial result
PubMed: PMID 31539622 · NCT03191396 (SUSTAIN 10) · Diabetes Mellitus, Type 2
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
Buse JB, Bode BW, Mertens A, et al. · BMJ Open Diabetes Res Care · 2021 · Trial result
PubMed: PMID 33318068 · NCT02849080 (PIONEER 7) · Diabetes Mellitus, Type 2
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
Araki E, Terauchi Y, Watada H, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 34472698 · NCT02906930 (PIONEER 1) · Diabetes Mellitus, Type 2
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S, McGuire DK, Bain SC, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32744418 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Verma S, Fainberg U, Husain M, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 33606902 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Verma S, Bain SC, Honoré JB, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32643857 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Thethi TK, Pratley R, Meier JJ, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32267058 · NCT02607865 (PIONEER 3) · Diabetes Mellitus, Type 2
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
Pratley RE, Crowley MJ, Gislum M, et al. · Diabetes Ther · 2021 · Derived
PubMed: PMID 33660198 · NCT02849080 (PIONEER 7) · Diabetes Mellitus, Type 2
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.
Pratley RE, Aroda VR, Catarig AM, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 33199417 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.
Overgaard RV, Navarria A, Ingwersen SH, et al. · Clin Pharmacokinet · 2021 · Derived
PubMed: PMID 33969456 · NCT02016911 · Diabetes Mellitus, Type 2
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Lingvay I, Capehorn MS, Catarig AM, et al. · J Clin Endocrinol Metab · 2021 · Derived
PubMed: PMID 32827435 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA, Bain SC, Bhatt DL, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32372454 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T, Mizuno A, Takaoka Y, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34693515 · NCT03574597 (SELECT) · Obesity
Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Jordy AB, Albayaty M, Breitschaft A, et al. · Clin Pharmacokinet · 2021 · Derived
PubMed: PMID 33782832 · NCT02845219 · Diabetes Mellitus, Type 2
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
Jódar E, Michelsen M, Polonsky W, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32227613 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.
Jensterle M, Ferjan S, Battelino T, et al. · Trials · 2021 · Derived
PubMed: PMID 34281590 · NCT04263415 · Dysgeusia
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M, Bain SC, Jeppesen OK, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 31903692 · NCT02305381 (SUSTAIN™ 5) · Diabetes Mellitus, Type 2
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M, Bain SC, Holst AG, et al. · Cardiovasc Diabetol · 2021 · Derived
PubMed: PMID 32998732 · NCT01930188 (SUSTAIN™ 2) · Diabetes Mellitus, Type 2
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
Harrison SA, Calanna S, Cusi K, et al. · Contemp Clin Trials · 2021 · Derived
PubMed: PMID 33039693 · NCT02970942 · Non-alcoholic Fatty Liver Disease
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34170647 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation.
Bækdal TA, Breitschaft A, Donsmark M, et al. · Diabetes Ther · 2021 · Derived
PubMed: PMID 34080123 · NCT01572753 · Diabetes Mellitus, Type 2
Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data.
Andersen G, Plum-Mörschel L, Hockings PD, et al. · Adv Ther · 2021 · Derived
PubMed: PMID 33006125 · NCT03357380 · Non-alcoholic Fatty Liver Disease
Metabolic syndrome and the risk of late onset Alzheimer's disease: An updated review and meta-analysis.
Zuin M, Roncon L, Passaro A, et al. · Nutr Metab Cardiovasc Dis · 2021 · Background
PubMed: PMID 34039508 · NCT06072963 · Metabolic Syndrome
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses.
Yozamp N, Vaidya A · Best Pract Res Clin Endocrinol Metab · 2021 · Background
PubMed: PMID 33593680 · NCT07361874 (IMPACT-MACS) · Weight Loss
Human adult cardiac autonomic innervation: Controversies in anatomical knowledge and relevance for cardiac neuromodulation.
Wink J, van Delft R, Notenboom RGE, et al. · Auton Neurosci · 2021 · Background
PubMed: PMID 32497872 · NCT06461377 · Diabetes Mellitus, Type 2
Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series.
Welling MS, de Groot CJ, Kleinendorst L, et al. · Clin Obes · 2021 · Background
PubMed: PMID 34291582 · NCT07302802
Pulmonary Aspiration of Gastric Contents: A Closed Claims Analysis.
Warner MA, Meyerhoff KL, Warner ME, et al. · Anesthesiology · 2021 · Background
PubMed: PMID 34019629 · NCT06154486 · Pneumonia, Aspiration
Health policy and public health implications of obesity in China.
Wang Y, Zhao L, Gao L, et al. · Lancet Diabetes Endocrinol · 2021 · Background
PubMed: PMID 34097869 · NCT05616052 · Body Weight Changes
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, et al. · Lancet Diabetes Endocrinol · 2021 · Background
PubMed: PMID 33662334 · NCT07430332 · Diabetes Mellitus, Type 1
Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations.
Trier C, Hollensted M, Schnurr TM, et al. · Int J Obes (Lond) · 2021 · Background
PubMed: PMID 32921795 · NCT05574439 (RESETTLE) · Weight Loss
Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
Thurston RC, Carroll JE, Levine M, et al. · J Clin Endocrinol Metab · 2021 · Background
PubMed: PMID 32080740 · NCT06975111
Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN.
Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. · J Am Heart Assoc · 2021 · Background
PubMed: PMID 33470142 · NCT06975111
A randomised trial examining inflammatory signaling in acutely induced hyperinsulinemia and hyperlipidemia in normal weight women-the reprometabolic syndrome.
Tannous A, Bradford AP, Kuhn K, et al. · PLoS One · 2021 · Background
PubMed: PMID 33764994 · NCT06975111
Plasma proteomic biomarker signature of age predicts health and life span.
Tanaka T, Basisty N, Fantoni G, et al. · Elife · 2021 · Background
PubMed: PMID 33210602 · NCT06975111
Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.
Takaku S, Tsukamoto M, Niimi N, et al. · Int J Mol Sci · 2021 · Background
PubMed: PMID 33804063 · NCT06461377 · Diabetes Mellitus, Type 2
Gastrointestinal peptides in eating-related disorders.
Smith KR, Moran TH · Physiol Behav · 2021 · Background
PubMed: PMID 33989649 · NCT06243536 · Diabetes Mellitus, Type 2
Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study.
Samargandy S, Matthews KA, Brooks MM, et al. · Menopause · 2021 · Background
PubMed: PMID 33651741 · NCT06975111
Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study.
Reimondo G, Castellano E, Grosso M, et al. · J Clin Endocrinol Metab · 2021 · Background
PubMed: PMID 31900474 · NCT07361874 (IMPACT-MACS) · Weight Loss
The Israel Registry for Alzheimer's Prevention (IRAP) Study: Design and Baseline Characteristics.
Ravona-Springer R, Sharvit-Ginon I, Ganmore I, et al. · J Alzheimers Dis · 2021 · Background
PubMed: PMID 33044181 · NCT06072963 · Metabolic Syndrome
Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
Qiu M, Ding LL, Zhang M, et al. · Diab Vasc Dis Res · 2021 · Background
PubMed: PMID 33887983 · NCT06072963 · Metabolic Syndrome
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Pratley RE, Catarig AM, Lingvay I, et al. · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 34286894 · NCT06243536 · Diabetes Mellitus, Type 2
Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress.
Moreau KL, Hildreth KL, Klawitter J, et al. · Geroscience · 2021 · Background
PubMed: PMID 32770384 · NCT06975111
Semaglutide for the Treatment of Type 2 Diabetes Mellitus.
Miles KE, Kerr JL · J Pharm Technol · 2021 · Background
PubMed: PMID 34861016 · NCT07043361 (Semaglutide) · Metabolic Diseases
Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.
Mehta K, Behl T, Kumar A, et al. · Curr Protein Pept Sci · 2021 · Background
PubMed: PMID 33292149 · NCT06461377 · Diabetes Mellitus, Type 2
Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Matza LS, Boye KS, Stewart KD, et al. · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 31646727 · NCT03724981 · Diabetes Mellitus, Type 2
Glycemic variability and cardiovascular disease in patients with type 2 diabetes.
Martinez M, Santamarina J, Pavesi A, et al. · BMJ Open Diabetes Res Care · 2021 · Background
PubMed: PMID 33762313 · NCT06243536 · Diabetes Mellitus, Type 2
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK, et al. · N Engl J Med · 2021 · Background
PubMed: PMID 33951361 · NCT05574439 (RESETTLE) · Weight Loss
Identification of astroglia-like cardiac nexus glia that are critical regulators of cardiac development and function.
Kikel-Coury NL, Brandt JP, Correia IA, et al. · PLoS Biol · 2021 · Background
PubMed: PMID 34793438 · NCT06461377 · Diabetes Mellitus, Type 2
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
Kellar D, Lockhart SN, Aisen P, et al. · J Prev Alzheimers Dis · 2021 · Background
PubMed: PMID 34101779 · NCT06072963 · Metabolic Syndrome
Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
Haidar A, Yale JF, Lovblom LE, et al. · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 33528904 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.
Godlewska BR, Harmer CJ · Psychopharmacology (Berl) · 2021 · Background
PubMed: PMID 31938879 · NCT06363487 (OxSENSE)
Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease.
Gaubert M, Lange C, Garnier-Crussard A, et al. · Alzheimers Res Ther · 2021 · Background
PubMed: PMID 33461618 · NCT06072963 · Metabolic Syndrome
Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
Frías JP, Nakhle S, Ruggles JA, et al. · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 27527911 · NCT06243536 · Diabetes Mellitus, Type 2
Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age.
Eren E, Hunt JFV, Shardell M, et al. · Alzheimers Dement · 2021 · Background
PubMed: PMID 32588967 · NCT06072963 · Metabolic Syndrome
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Dejgaard TF, Schmidt S, Frandsen CS, et al. · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 31696598 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Technology in the management of type 2 diabetes: Present status and future prospects.
Daly A, Hovorka R · Diabetes Obes Metab · 2021 · Background
PubMed: PMID 33950566 · NCT06243536 · Diabetes Mellitus, Type 2
Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
Da Porto A, Casarsa V, Colussi G, et al. · Diabetes Metab Syndr · 2021 · Background
PubMed: PMID 32289741 · NCT06243536 · Diabetes Mellitus, Type 2
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
Craft S, Raman R, Chow TW, et al. · JAMA Neurol · 2021 · Background
PubMed: PMID 32568367 · NCT06072963 · Metabolic Syndrome
Implication of Heterozygous Variants in Genes of the Leptin-Melanocortin Pathway in Severe Obesity.
Courbage S, Poitou C, Le Beyec-Le Bihan J, et al. · J Clin Endocrinol Metab · 2021 · Background
PubMed: PMID 34097736 · NCT07302802
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.
Cho L, Davis M, Elgendy I, et al. · J Am Coll Cardiol · 2021 · Background
PubMed: PMID 32439010 · NCT06975111
Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.
Chang YF, Zhang D, Hu WM, et al. · J Clin Neurosci · 2021 · Background
PubMed: PMID 33222922 · NCT06072963 · Metabolic Syndrome
Physiology of Energy Intake in the Weight-Reduced State.
Berthoud HR, Seeley RJ, Roberts SB, et al. · Obesity (Silver Spring) · 2021 · Background
PubMed: PMID 33759396 · NCT07457424 (DIGRAT) · Obesity
Approach to the Patient With Adrenal Incidentaloma.
Bancos I, Prete A · J Clin Endocrinol Metab · 2021 · Background
PubMed: PMID 34260734 · NCT07361874 (IMPACT-MACS) · Weight Loss
Computerized Cognitive Training for Older Adults at Higher Dementia Risk due to Diabetes: Findings From a Randomized Controlled Trial.
Bahar-Fuchs A, Barendse MEA, Bloom R, et al. · J Gerontol A Biol Sci Med Sci · 2021 · Background
PubMed: PMID 30868154 · NCT06072963 · Metabolic Syndrome
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI, Ferrucci L, Kapogiannis D, et al. · Ageing Res Rev · 2021 · Background
PubMed: PMID 33831607 · NCT06072963 · Metabolic Syndrome
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Ashton NJ, Pascoal TA, Karikari TK, et al. · Acta Neuropathol · 2021 · Background
PubMed: PMID 33585983 · NCT06072963 · Metabolic Syndrome
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J, Fitch A, Fruh S, et al. · Adv Ther · 2021 · Background
PubMed: PMID 33977495 · NCT07513168 · Obesity
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
Andersen A, Knop FK, Vilsbøll T, et al. · Drugs · 2021 · Background
PubMed: PMID 33964002 · NCT07043361 (Semaglutide) · Metabolic Diseases
Gastroparesis With the Initiation of Liraglutide: A Case Report.
Almustanyir S, Alhabeeb H, AlHusseini N, et al. · Cureus · 2021 · Background
PubMed: PMID 33403167 · NCT06154486 · Pneumonia, Aspiration
Anatomy and Physiology of Intrinsic Cardiac Autonomic Nervous System: Da Vinci Anatomy Card #2.
Aksu T, Gupta D, Pauza DH, et al. · JACC Case Rep · 2021 · Background
PubMed: PMID 34317590 · NCT06461377 · Diabetes Mellitus, Type 2

2020 (59 papers)

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B, Bhosekar V, Busch R, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 30833170 · NCT03086330 (SUSTAIN 9) · Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Zinman B, Aroda VR, Buse JB, et al. · Diabetes Care · 2020 · Trial result
PubMed: PMID 31530667 · NCT03021187 (PIONEER 8) · Diabetes Mellitus, Type 2
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D, Nakamura J, Kaneto H, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 32333876 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
Wilkinson L, Hunt B, Johansen P, et al. · Diabetes Ther · 2020 · Trial result
PubMed: PMID 29557057 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A, Hoxer CS, Johansen P, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 30362224 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes.
Terenzi DC, Al-Omran M, Quan A, et al. · JACC Basic Transl Sci · 2020 · Trial result
PubMed: PMID 30847424 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Ryan DH, Lingvay I, Colhoun HM, et al. · Am Heart J · 2020 · Trial result
PubMed: PMID 32916609 · NCT03574597 (SELECT) · Obesity
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Rodbard HW, Rosenstock J, Canani LH, et al. · Diabetes Care · 2020 · Trial result
PubMed: PMID 31530666 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
Acute Ischemic Stroke.
Powers WJ · N Engl J Med · 2020 · Trial result
PubMed: PMID 32668115 · NCT07030621 (STARS) · Ischemic Stroke
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Powers WJ, Rabinstein AA, Ackerson T, et al. · Stroke · 2020 · Trial result
PubMed: PMID 31662037 · NCT07030621 (STARS) · Ischemic Stroke
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 31189520 · NCT02849080 (PIONEER 7) · Diabetes Mellitus, Type 2
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O, Blicher TM, Rosenlund S, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 31189517 · NCT02827708 (PIONEER 5) · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Malkin SJP, Russel-Szymczyk M, Liidemann G, et al. · Diabetes Ther · 2020 · Trial result
PubMed: PMID 30535837 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I, Catarig AM, Frias JP, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 31540867 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA, Bain SC, Hramiak I, et al. · Cardiovasc Diabetol · 2020 · Trial result
PubMed: PMID 31167654 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Hess DA, Terenzi DC, Trac JZ, et al. · Cell Metab · 2020 · Trial result
PubMed: PMID 31477497 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Han Y, Li Y, He B, et al. · Reprod Biomed Online · 2020 · Trial result
PubMed: PMID 31229399 · NCT05702905 · Obesity
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects.
Demmel V, Sandberg-Schaal A, Jacobsen JB, et al. · Diabetes Ther · 2020 · Trial result
PubMed: PMID 29799100 · NCT02064348 · Diabetes Mellitus
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
Carlsson Petri KC, Ingwersen SH, Flint A, et al. · Diabetes Ther · 2020 · Trial result
PubMed: PMID 29907893 · NCT02054897 (SUSTAIN™1) · Diabetes Mellitus, Type 2
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC, Mosenzon O, Arechavaleta R, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 30284349 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes Care · 2020 · Trial result
PubMed: PMID 31186300 · NCT02906930 (PIONEER 1) · Diabetes Mellitus, Type 2
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR, Ahmann A, Cariou B, et al. · Diabetes Metab · 2020 · Trial result
PubMed: PMID 30615985 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
PubMed: PMID 32333875 · NCT03018028 (PIONEER 9) · Diabetes Mellitus, Type 2
Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle J, Birkenfeld AL, Polonsky WH, et al. · Diabetes Obes Metab · 2020 · Derived
PubMed: PMID 31215727 · NCT02305381 (SUSTAIN™ 5) · Diabetes Mellitus, Type 2
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C, Donsmark M, Blicher TM, et al. · Clin Pharmacokinet · 2020 · Derived
PubMed: PMID 30565096 · NCT01686945 · Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
DeSouza C, Cariou B, Garg S, et al. · J Clin Endocrinol Metab · 2020 · Derived
PubMed: PMID 31769496 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Capehorn M, Ghani Y, Hindsberger C, et al. · Diabetes Ther · 2020 · Derived
PubMed: PMID 32193837 · NCT03191396 (SUSTAIN 10) · Diabetes Mellitus, Type 2
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Verma S, Bain SC, Monk Fries T, et al. · Diabetes Obes Metab · 2020 · Background
PubMed: PMID 30851070 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
van Eyk HJ, Paiman EHM, Bizino MB, et al. · Nutr Metab Cardiovasc Dis · 2020 · Background
PubMed: PMID 32127340 · NCT05419726 · Obesity
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Saeedi P, Petersohn I, Salpea P, et al. · Diabetes Res Clin Pract · 2020 · Background
PubMed: PMID 31518657 · NCT06243536 · Diabetes Mellitus, Type 2
Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.
Pradhan A, Vohra S, Vishwakarma P, et al. · J Family Med Prim Care · 2020 · Background
PubMed: PMID 31334145 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.
Pozzi M, Mazhar F, Peeters GGAM, et al. · J Affect Disord · 2020 · Background
PubMed: PMID 31153593 · NCT06363487 (OxSENSE)
Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury.
Posti JP, Takala RSK, Lagerstedt L, et al. · J Neurotrauma · 2020 · Background
PubMed: PMID 30760178 · NCT06072963 · Metabolic Syndrome
Is Vitamin D Supplementation Useful for Weight Loss Programs? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Perna S · Medicina (Kaunas) · 2020 · Background
PubMed: PMID 31336940 · NCT07043361 (Semaglutide) · Metabolic Diseases
The role of adipose tissue in cardiovascular health and disease.
Oikonomou EK, Antoniades C · Nat Rev Cardiol · 2020 · Background
PubMed: PMID 30287946 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Clinical importance of epicardial adipose tissue.
Nagy E, Jermendy AL, Merkely B, et al. · Arch Med Sci · 2020 · Background
PubMed: PMID 28721155 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Glucagon-like peptide 1 (GLP-1).
Müller TD, Finan B, Bloom SR, et al. · Mol Metab · 2020 · Background
PubMed: PMID 31767182 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP, Russel-Szymczyk M, Psota M, et al. · Adv Ther · 2020 · Background
PubMed: PMID 31168765 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Waist circumference in relation to outcomes of infertility treatment with assisted reproductive technologies.
Li MC, Mínguez-Alarcón L, Arvizu M, et al. · Am J Obstet Gynecol · 2020 · Background
PubMed: PMID 30763543 · NCT07242534 (SEQ) · Obesity
Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial.
Lemieux P, Weisnagel SJ, Caron AZ, et al. · Eur J Endocrinol · 2020 · Background
PubMed: PMID 31344685 · NCT07043361 (Semaglutide) · Metabolic Diseases
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF, Calanna S, Davies M, et al. · Obesity (Silver Spring) · 2020 · Background
PubMed: PMID 32441473 · NCT03548935 (STEP 1) · Obesity
Cerebral Small Vessel Disease and Alzheimer's Disease: A Review.
Kim HW, Hong J, Jeon JC, et al. · Front Neurol · 2020 · Background
PubMed: PMID 32982937 · NCT06072963 · Metabolic Syndrome
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM, Cho YK, Lee J, et al. · Diabetes Metab J · 2020 · Background
PubMed: PMID 30604598 · NCT07043361 (Semaglutide) · Metabolic Diseases
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Johansen NJ, Dejgaard TF, Lund A, et al. · Lancet Diabetes Endocrinol · 2020 · Background
PubMed: PMID 32135138 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M, Janez A, Fliers E, et al. · Hum Reprod Update · 2020 · Background
PubMed: PMID 31260047 · NCT07242534 (SEQ) · Obesity
Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.
Janssen LGM, Nahon KJ, Bracké KFM, et al. · Metabolism · 2020 · Background
PubMed: PMID 31982480 · NCT05419726 · Obesity
Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women.
He Y, Lu Y, Zhu Q, et al. · Am J Obstet Gynecol · 2020 · Background
PubMed: PMID 30910544 · NCT07242534 (SEQ) · Obesity
Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression.
Hamer JA, Testani D, Mansur RB, et al. · Exp Neurol · 2020 · Background
PubMed: PMID 30695707 · NCT06363487 (OxSENSE)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Gerstein HC, Hart R, Colhoun HM, et al. · Lancet Diabetes Endocrinol · 2020 · Background
PubMed: PMID 31924562 · NCT06072963 · Metabolic Syndrome
Reversal of epigenetic aging and immunosenescent trends in humans.
Fahy GM, Brooke RT, Watson JP, et al. · Aging Cell · 2020 · Background
PubMed: PMID 31496122 · NCT06975111
The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN).
El Khoudary SR, Greendale G, Crawford SL, et al. · Menopause · 2020 · Background
PubMed: PMID 31568098 · NCT06975111
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study.
Ebbehoj A, Li D, Kaur RJ, et al. · Lancet Diabetes Endocrinol · 2020 · Background
PubMed: PMID 33065059 · NCT07361874 (IMPACT-MACS) · Weight Loss
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Douros A, Lix LM, Fralick M, et al. · Ann Intern Med · 2020 · Background
PubMed: PMID 32716707 · NCT06072963 · Metabolic Syndrome
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. · Lancet Neurol · 2020 · Background
PubMed: PMID 32562683 · NCT06072963 · Metabolic Syndrome
Semaglutide as a promising antiobesity drug.
Christou GA, Katsiki N, Blundell J, et al. · Obes Rev · 2020 · Background
PubMed: PMID 30768766 · NCT06287307 (SEABAR) · Obesity
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Battelino T, Danne T, Bergenstal RM, et al. · Diabetes Care · 2020 · Background
PubMed: PMID 31177185 · NCT06243536 · Diabetes Mellitus, Type 2
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Bækdal TA, Borregaard J, Hansen CW, et al. · Clin Pharmacokinet · 2020 · Background
PubMed: PMID 30945118 · NCT02070510 · Diabetes Mellitus
Metabolic Syndrome, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Longitudinal Studies.
Atti AR, Valente S, Iodice A, et al. · Am J Geriatr Psychiatry · 2020 · Background
PubMed: PMID 30917904 · NCT06072963 · Metabolic Syndrome
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
Aroda VR, Saugstrup T, Buse JB, et al. · Diabetes Obes Metab · 2020 · Background
PubMed: PMID 31168921 · NCT02906930 (PIONEER 1) · Diabetes Mellitus, Type 2

2019 (52 papers)

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.
Warren M, Chaykin L, Trachtenbarg D, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29687620 · NCT02054897 (SUSTAIN™1) · Diabetes Mellitus, Type 2
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
Vilsbøll T, Bain SC, Leiter LA, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29178519 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R, Wilkinson L, Vrazic H, et al. · Curr Med Res Opin · 2019 · Trial result
PubMed: PMID 29764222 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Resource recovery from sulphate-rich sewage through an innovative anaerobic-based water resource recovery facility (WRRF).
Seco A, Aparicio S, González-Camejo J, et al. · Water Sci Technol · 2019 · Trial result
PubMed: PMID 30566096 · NCT01686945 · Diabetes Mellitus, Type 2
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J, Allison D, Birkenfeld AL, et al. · JAMA · 2019 · Trial result
PubMed: PMID 30903796 · NCT02607865 (PIONEER 3) · Diabetes Mellitus, Type 2
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R, Amod A, Hoff ST, et al. · Lancet · 2019 · Trial result
PubMed: PMID 31186120 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
Petri KCC, Ingwersen SH, Flint A, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29748996 · NCT01930188 (SUSTAIN™ 2) · Diabetes Mellitus, Type 2
Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Overgaard RV, Lindberg SØ, Thielke D, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 30047216 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
Korsatko S, Jensen L, Brunner M, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29893488 · NCT02147431 · Diabetes Mellitus, Type 2
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K, Yamada Y, Watada H, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29322610 · NCT02207374 (SUSTAIN™) · Diabetes Mellitus, Type 2
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
Jensen L, Kupcova V, Arold G, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29205786 · NCT02210871 · Diabetes Mellitus, Type 2
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I, Jensen L, Flint A, et al. · Adv Ther · 2019 · Trial result
PubMed: PMID 29536338 · NCT02146079 · Diabetes Mellitus, Type 2
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M, Birkenfeld AL, Donsmark M, et al. · N Engl J Med · 2019 · Trial result
PubMed: PMID 31185157 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C, Søndergaard FL, Thomsen M, et al. · Clin Pharmacokinet · 2019 · Trial result
PubMed: PMID 29623579 · NCT02014259 · Diabetes Mellitus, Type 2
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
DeVries JH, Desouza C, Bellary S, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29862621 · NCT01930188 (SUSTAIN™ 2) · Diabetes Mellitus, Type 2
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
Baekdal TA, Thomsen M, Kupčová V, et al. · J Clin Pharmacol · 2019 · Trial result
PubMed: PMID 29693715 · NCT02016911 · Diabetes Mellitus, Type 2
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.
Ahrén B, Atkin SL, Charpentier G, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29766634 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET, Eudicone JM, Bell KF, et al. · Am J Manag Care · 2019 · Derived
PubMed: PMID 29693361 · NCT01720446 (SUSTAIN™ 6) · Diabetes Mellitus, Type 2
A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women.
Subih HS, Zueter Z, Obeidat BM, et al. · Nutr Res · 2019 · Background
PubMed: PMID 30442233 · NCT07043361 (Semaglutide) · Metabolic Diseases
Recent updates on GLP-1 agonists: Current advancements & challenges.
Sharma D, Verma S, Vaidya S, et al. · Biomed Pharmacother · 2019 · Background
PubMed: PMID 30372907 · NCT06243536 · Diabetes Mellitus, Type 2
Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy.
Scally C, Abbas H, Ahearn T, et al. · Circulation · 2019 · Background
PubMed: PMID 30586731 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Are women with obesity and infertility willing to attempt weight loss prior to fertility treatment?
Sacha CR, Page CM, Goldman RH, et al. · Obes Res Clin Pract · 2019 · Background
PubMed: PMID 29221938 · NCT07242534 (SEQ) · Obesity
Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations.
Russo R, Di Iorio B, Di Lullo L, et al. · J Nephrol · 2019 · Background
PubMed: PMID 29704210 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, et al. · Diabetes Care · 2019 · Background
PubMed: PMID 30287422 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
Rodbard HW, Bellary S, Hramiak I, et al. · Endocr Pract · 2019 · Background
PubMed: PMID 30865526 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer's Disease.
Robinson A, Lubitz I, Atrakchi-Baranes D, et al. · J Mol Neurosci · 2019 · Background
PubMed: PMID 30635783 · NCT06072963 · Metabolic Syndrome
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Riddle MC, Cefalu WT · Diabetes Care · 2019 · Background
PubMed: PMID 30459245 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis.
Pal K, Mukadam N, Petersen I, et al. · Soc Psychiatry Psychiatr Epidemiol · 2019 · Background
PubMed: PMID 30182156 · NCT06072963 · Metabolic Syndrome
Recent advances in the detection of brown adipose tissue in adult humans: a review.
Ong FJ, Ahmed BA, Oreskovich SM, et al. · Clin Sci (Lond) · 2019 · Background
PubMed: PMID 29802209 · NCT05419726 · Obesity
Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
Novak P, Pimentel Maldonado DA, Novak V, et al. · PLoS One · 2019 · Background
PubMed: PMID 31022213 · NCT06072963 · Metabolic Syndrome
Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity.
Lee SJ, Sanchez-Watts G, Krieger JP, et al. · Mol Metab · 2019 · Background
PubMed: PMID 29650350 · NCT05419726 · Obesity
The Role of Epicardial Fat in Pericardial Diseases.
Lazaros G, Antonopoulos A, Antoniades C, et al. · Curr Cardiol Rep · 2019 · Background
PubMed: PMID 29675684 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Diagnostic Accuracy of Point-of-Care Gastric Ultrasound.
Kruisselbrink R, Gharapetian A, Chaparro LE, et al. · Anesth Analg · 2019 · Background
PubMed: PMID 29624530 · NCT06154486 · Pneumonia, Aspiration
Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats.
Krieger JP, Santos da Conceição EP, Sanchez-Watts G, et al. · Am J Physiol Regul Integr Comp Physiol · 2019 · Background
PubMed: PMID 29847161 · NCT05419726 · Obesity
Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.
Kolotkin RL, Williams VSL, Ervin CM, et al. · Clin Obes · 2019 · Background
PubMed: PMID 30993900 · NCT02906930 (PIONEER 1) · Diabetes Mellitus, Type 2
Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents.
Katsel P, Roussos P, Beeri MS, et al. · PLoS One · 2019 · Background
PubMed: PMID 30383799 · NCT06072963 · Metabolic Syndrome
Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
Iepsen EW, Zhang J, Thomsen HS, et al. · Cell Metab · 2019 · Background
PubMed: PMID 29861388 · NCT05574439 (RESETTLE) · Weight Loss
A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling.
Hsu TM, Noble EE, Liu CM, et al. · Mol Psychiatry · 2019 · Background
PubMed: PMID 28461695 · NCT06243536 · Diabetes Mellitus, Type 2
Pericardial Adipose Tissue Regulates Granulopoiesis, Fibrosis, and Cardiac Function After Myocardial Infarction.
Horckmans M, Bianchini M, Santovito D, et al. · Circulation · 2019 · Background
PubMed: PMID 29167227 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease.
Heiss WD · J Nucl Med · 2019 · Background
PubMed: PMID 29959217 · NCT06072963 · Metabolic Syndrome
How do antidepressants work? New perspectives for refining future treatment approaches.
Harmer CJ, Duman RS, Cowen PJ, et al. · Lancet Psychiatry · 2019 · Background
PubMed: PMID 28153641 · NCT06363487 (OxSENSE)
GLP-1 Receptor Agonists and Kidney Protection.
Greco EV, Russo G, Giandalia A, et al. · Medicina (Kaunas) · 2019 · Background
PubMed: PMID 31159279 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Glucagon, GLP-1 and Thermogenesis.
González-García I, Milbank E, Diéguez C, et al. · Int J Mol Sci · 2019 · Background
PubMed: PMID 31337027 · NCT05419726 · Obesity
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019 · Background
PubMed: PMID 31189511 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Non-Water-Suppressed 1H MR Spectroscopy with Orientational Prior Knowledge Shows Potential for Separating Intra- and Extramyocellular Lipid Signals in Human Myocardium.
Fillmer A, Hock A, Cameron D, et al. · Sci Rep · 2019 · Background
PubMed: PMID 29203776 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, et al. · Trials · 2019 · Background
PubMed: PMID 30944040 · NCT06072963 · Metabolic Syndrome
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ · Cell Metab · 2019 · Background
PubMed: PMID 29617641 · NCT06243536 · Diabetes Mellitus, Type 2
Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity.
Christensen BJ, Iepsen EW, Lundgren J, et al. · Obes Facts · 2019 · Background
PubMed: PMID 29207396 · NCT05574439 (RESETTLE) · Weight Loss
Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015.
Cheng YJ, Imperatore G, Geiss LS, et al. · Diabetes Care · 2019 · Background
PubMed: PMID 30131397 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management.
Busetto L, Dicker D, Azran C, et al. · Obes Facts · 2019 · Background
PubMed: PMID 29207379 · NCT06287307 (SEABAR) · Obesity
Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease.
Bromberger JT, Epperson CN · Obstet Gynecol Clin North Am · 2019 · Background
PubMed: PMID 30401549 · NCT06975111
2019 May 4
· 2019 · Background
PubMed: PMID 31689026 · NCT07513168 · Obesity

2018 (37 papers)

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
PubMed: PMID 28110911 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y, Terauchi Y, Osonoi T, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28786547 · NCT02254291 (SUSTAIN™) · Diabetes Mellitus, Type 2
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Salamun V, Jensterle M, Janez A, et al. · Eur J Endocrinol · 2018 · Trial result
PubMed: PMID 29703793 · NCT05702905 · Obesity
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW, Lingvay I, Reed J, et al. · J Clin Endocrinol Metab · 2018 · Trial result
PubMed: PMID 29688502 · NCT02305381 (SUSTAIN™ 5) · Diabetes Mellitus, Type 2
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
PubMed: PMID 29397376 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease.
Patel VB, Shah S, Verma S, et al. · Heart Fail Rev · 2018 · Trial result
PubMed: PMID 28762019 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, et al. · Lancet · 2018 · Trial result
PubMed: PMID 30122305 · NCT02453711 · Obesity
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC, Flint A, Jacobsen JB, et al. · Clin Pharmacokinet · 2018 · Trial result
PubMed: PMID 28349386 · NCT00833716 · Diabetes Mellitus, Type 2
Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
Liu X, Zhang Y, Zheng SY, et al. · Clin Endocrinol (Oxf) · 2018 · Trial result
PubMed: PMID 28834553 · NCT05702905 · Obesity
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Lingvay I, Desouza CV, Lalic KS, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 30026333 · NCT02461589 · Diabetes Mellitus, Type 2
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Kapitza C, Dahl K, Jacobsen JB, et al. · Diabetologia · 2018 · Trial result
PubMed: PMID 28526920 · NCT02212067 · Diabetes Mellitus, Type 2
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.
Jensen L, Helleberg H, Roffel A, et al. · Eur J Pharm Sci · 2018 · Trial result
PubMed: PMID 28323117 · NCT02060266 · Diabetes Mellitus
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Hjerpsted JB, Flint A, Brooks A, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28941314 · NCT02079870 · Obesity
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Hausner H, Derving Karsbøl J, Holst AG, et al. · Clin Pharmacokinet · 2018 · Trial result
PubMed: PMID 28349387 · NCT02243098 · Diabetes Mellitus
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
Cefalu WT, Kaul S, Gerstein HC, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29263194 · NCT02692716 (PIONEER 6) · Diabetes Mellitus, Type 2
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J, Finlayson G, Axelsen M, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28266779 · NCT02079870 · Obesity
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA, Breitschaft A, Navarria A, et al. · Expert Opin Drug Metab Toxicol · 2018 · Trial result
PubMed: PMID 29897249 · NCT02249871 · Diabetes Mellitus
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR, Bain SC, Cariou B, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
PubMed: PMID 28344112 · NCT02128932 (SUSTAIN™ 4) · Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, Masmiquel L, Kumar H, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
PubMed: PMID 28385659 · NCT01930188 (SUSTAIN™ 2) · Diabetes Mellitus, Type 2
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann AJ, Capehorn M, Charpentier G, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29246950 · NCT01885208 (SUSTAIN™ 3) · Diabetes Mellitus, Type 2
Obesity as disruptor of the female fertility.
Silvestris E, de Pergola G, Rosania R, et al. · Reprod Biol Endocrinol · 2018 · Background
PubMed: PMID 29523133 · NCT07242534 (SEQ) · Obesity
Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.
Reges O, Greenland P, Dicker D, et al. · JAMA · 2018 · Background
PubMed: PMID 29340677 · NCT06287307 (SEABAR) · Obesity
Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration.
Anesthesiology · 2018 · Background
PubMed: PMID 28045707 · NCT06154486 · Pneumonia, Aspiration
Reoperative Bariatric Surgery: a Systematic Review of the Reasons for Surgery, Medical and Weight Loss Outcomes, Relevant Behavioral Factors.
Pinto-Bastos A, Conceição EM, Machado PPP, et al. · Obes Surg · 2018 · Background
PubMed: PMID 28791623 · NCT06287307 (SEABAR) · Obesity
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM, Aroda VR, Astrup A, et al. · Diabetes Obes Metab · 2018 · Background
PubMed: PMID 28386912 · NCT06363487 (OxSENSE)
Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls.
Nordang GBN, Busk ØL, Tveten K, et al. · Mol Genet Metab · 2018 · Background
PubMed: PMID 28377240 · NCT07302802
Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis.
Nieto-Martínez R, González-Rivas JP, Medina-Inojosa JR, et al. · Curr Diab Rep · 2018 · Background
PubMed: PMID 29168047 · NCT06243536 · Diabetes Mellitus, Type 2
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature.
McElroy SL, Mori N, Guerdjikova AI, et al. · Med Hypotheses · 2018 · Background
PubMed: PMID 29407005 · NCT06243536 · Diabetes Mellitus, Type 2
Predictive value of telomere length on outcome following acute myocardial infarction: evidence for contrasting effects of vascular vs. blood oxidative stress.
Margaritis M, Sanna F, Lazaros G, et al. · Eur Heart J · 2018 · Background
PubMed: PMID 28444175 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Aerobic exercise promotes executive functions and impacts functional neural activity among older adults with vascular cognitive impairment.
Hsu CL, Best JR, Davis JC, et al. · Br J Sports Med · 2018 · Background
PubMed: PMID 28432077 · NCT06072963 · Metabolic Syndrome
A Proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk.
Hebebrand J, Holm JC, Woodward E, et al. · Obes Facts · 2018 · Background
PubMed: PMID 28738325 · NCT05574439 (RESETTLE) · Weight Loss
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H, Khemani D, Eckert D, et al. · Lancet Gastroenterol Hepatol · 2018 · Background
PubMed: PMID 28958851 · NCT06154486 · Pneumonia, Aspiration
Eating disoders in type 2 diabetic people: Brief review.
García-Mayor RV, García-Soidán FJ · Diabetes Metab Syndr · 2018 · Background
PubMed: PMID 27575047 · NCT06243536 · Diabetes Mellitus, Type 2
Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time.
Fisher L, Hessler D, Polonsky W, et al. · J Diabetes Complications · 2018 · Background
PubMed: PMID 27118163 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Craft S, Claxton A, Baker LD, et al. · J Alzheimers Dis · 2018 · Background
PubMed: PMID 28372335 · NCT06072963 · Metabolic Syndrome
Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
Bjerregaard LG, Jensen BW, Ängquist L, et al. · N Engl J Med · 2018 · Background
PubMed: PMID 29617589 · NCT05574439 (RESETTLE) · Weight Loss
Detecting human coronary inflammation by imaging perivascular fat.
Antonopoulos AS, Sanna F, Sabharwal N, et al. · Sci Transl Med · 2018 · Background
PubMed: PMID 28701474 · NCT06557811 (SemaFatCard) · Diabetes Mellitus

2017 (23 papers)

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M, Pieber TR, Hartoft-Nielsen ML, et al. · JAMA · 2017 · Trial result
PubMed: PMID 29049653 · NCT01923181 · Diabetes Mellitus, Type 2
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Ang JE, Pandher R, Ang JC, et al. · Mol Cancer Ther · 2017 · Trial result
PubMed: PMID 27048952 · NCT06057077 · Diabetes Mellitus, Type 1
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Young LH, Viscoli CM, Curtis JP, et al. · Circulation · 2017 · Background
PubMed: PMID 28246237 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss.
Tsaban G, Wolak A, Avni-Hassid H, et al. · Am J Clin Nutr · 2017 · Background
PubMed: PMID 28814394 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Tkáč I, Raz I · Diabetes Care · 2017 · Background
PubMed: PMID 27659407 · NCT06827002 · Obesity
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y, Kuwata H, Yabe D, et al. · J Diabetes Investig · 2017 · Background
PubMed: PMID 27186364 · NCT07043361 (Semaglutide) · Metabolic Diseases
Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
Rodríguez-Gutiérrez R, Montori VM · Circ Cardiovasc Qual Outcomes · 2017 · Background
PubMed: PMID 27553599 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
A hospital-based child and adolescent overweight and obesity treatment protocol transferred into a community healthcare setting.
Mollerup PM, Gamborg M, Trier C, et al. · PLoS One · 2017 · Background
PubMed: PMID 28264043 · NCT05574439 (RESETTLE) · Weight Loss
Age-dependent differences in brain tissue microstructure assessed with neurite orientation dispersion and density imaging.
Merluzzi AP, Dean DC, Adluru N, et al. · Neurobiol Aging · 2017 · Background
PubMed: PMID 27255817 · NCT06072963 · Metabolic Syndrome
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Mathieu C, Zinman B, Hemmingsson JU, et al. · Diabetes Care · 2017 · Background
PubMed: PMID 27506222 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
Mansur RB, Ahmed J, Cha DS, et al. · J Affect Disord · 2017 · Background
PubMed: PMID 27721184 · NCT06363487 (OxSENSE)
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. · N Engl J Med · 2017 · Background
PubMed: PMID 28854085 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Cerebrovascular disease in ageing and Alzheimer's disease.
Love S, Miners JS · Acta Neuropathol · 2017 · Background
PubMed: PMID 26711459 · NCT06072963 · Metabolic Syndrome
Glucose and GTP-binding protein-coupled receptor cooperatively regulate transient receptor potential-channels to stimulate insulin secretion [Review].
Kakei M, Yoshida M, Dezaki K, et al. · Endocr J · 2017 · Background
PubMed: PMID 27321586 · NCT07043361 (Semaglutide) · Metabolic Diseases
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.
Iepsen EW, Lundgren J, Holst JJ, et al. · Eur J Endocrinol · 2017 · Background
PubMed: PMID 26976129 · NCT05574439 (RESETTLE) · Weight Loss
Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults.
Hoscheidt SM, Kellawan JM, Berman SE, et al. · J Cereb Blood Flow Metab · 2017 · Background
PubMed: PMID 27488909 · NCT06072963 · Metabolic Syndrome
Epicardial adipose tissue volume estimation by postmortem computed tomography of eviscerated hearts.
Hindsø L, Jakobsen LS, Jacobsen C, et al. · Forensic Sci Med Pathol · 2017 · Background
PubMed: PMID 29098638 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. · N Engl J Med · 2017 · Background
PubMed: PMID 28604169 · NCT05574439 (RESETTLE) · Weight Loss
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.
FLAT-SUGAR Trial Investigators · Diabetes Care · 2017 · Background
PubMed: PMID 27208320 · NCT06243536 · Diabetes Mellitus, Type 2
Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease.
Daulatzai MA · J Neurosci Res · 2017 · Background
PubMed: PMID 27350397 · NCT06072963 · Metabolic Syndrome
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
Bouchi R, Terashima M, Sasahara Y, et al. · Cardiovasc Diabetol · 2017 · Background
PubMed: PMID 28253918 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Eating Behavior, Low-Frequency Functional Mutations in the Melanocortin-4 Receptor (MC4R) Gene, and Outcomes of Bariatric Operations: A 6-Year Prospective Study.
Bonnefond A, Keller R, Meyre D, et al. · Diabetes Care · 2017 · Background
PubMed: PMID 27222505 · NCT05574439 (RESETTLE) · Weight Loss
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Ahrén B, Hirsch IB, Pieber TR, et al. · Diabetes Care · 2017 · Background
PubMed: PMID 27493132 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1

2016 (31 papers)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016 · Trial result
PubMed: PMID 27633186 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M, Kravos NA, Pfeifer M, et al. · Hormones (Athens) · 2016 · Trial result
PubMed: PMID 25885106 · NCT05702905 · Obesity
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA, Petrie JR, Sesti G, et al. · Diabetes Care · 2016 · Derived
PubMed: PMID 26358288 · NCT00696657 · Diabetes Mellitus, Type 2
European Guidelines for Obesity Management in Adults.
Yumuk V, Tsigos C, Fried M, et al. · Obes Facts · 2016 · Background
PubMed: PMID 26641646 · NCT06287307 (SEABAR) · Obesity
The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.
Suchankova P, Yan J, Schwandt ML, et al. · Transl Psychiatry · 2016 · Background
PubMed: PMID 26080318 · NCT06015893 · Alcoholism
Prognostic value of epicardial fat volume measurements by computed tomography: a systematic review of the literature.
Spearman JV, Renker M, Schoepf UJ, et al. · Eur Radiol · 2016 · Background
PubMed: PMID 25925354 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis.
Skubleny D, Switzer NJ, Gill RS, et al. · Obes Surg · 2016 · Background
PubMed: PMID 26431698 · NCT05646199 · Polycystic Ovary Syndrome
User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF, Kushner P, Aguilar R, et al. · Postgrad Med · 2016 · Background
PubMed: PMID 26371721 · NCT06287307 (SEABAR) · Obesity
Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
Robert SA, Rohana AG, Shah SA, et al. · Obes Res Clin Pract · 2016 · Background
PubMed: PMID 25870084 · NCT06243536 · Diabetes Mellitus, Type 2
[CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES].
Rahelić D, Altabas V, Bakula M, et al. · Lijec Vjesn · 2016 · Background
PubMed: PMID 27443001 · NCT06243536 · Diabetes Mellitus, Type 2
I-AIM framework for point-of-care gastric ultrasound.
Perlas A, Van de Putte P, Van Houwe P, et al. · Br J Anaesth · 2016 · Background
PubMed: PMID 25951832 · NCT06154486 · Pneumonia, Aspiration
Effect of iterative reconstruction on variability and reproducibility of epicardial fat volume quantification by cardiac CT.
Oda S, Utsunomiya D, Funama Y, et al. · J Cardiovasc Comput Tomogr · 2016 · Background
PubMed: PMID 26560351 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W, Trujillo JM, Megyeri J, et al. · Ann Pharmacother · 2016 · Background
PubMed: PMID 26887340 · NCT06287307 (SEABAR) · Obesity
Eating disorders are frequent among type 2 diabetic patients and are associated with worse metabolic and psychological outcomes: results from a cross-sectional study in primary and secondary care settings.
Nicolau J, Simó R, Sanchís P, et al. · Acta Diabetol · 2016 · Background
PubMed: PMID 25841588 · NCT06243536 · Diabetes Mellitus, Type 2
Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.
Moulton CD, Pickup JC, Amiel SA, et al. · Prim Care Diabetes · 2016 · Background
PubMed: PMID 26137918 · NCT06363487 (OxSENSE)
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Mogul H, Freeman R, Nguyen K, et al. · Endocr Pract · 2016 · Background
PubMed: PMID 26789348 · NCT06975111
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 27295427 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Classification of eating disorders: comparison of relative prevalence rates using DSM-IV and DSM-5 criteria.
Mancuso SG, Newton JR, Bosanac P, et al. · Br J Psychiatry · 2016 · Background
PubMed: PMID 25745131 · NCT06243536 · Diabetes Mellitus, Type 2
Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes.
Levelt E, Mahmod M, Piechnik SK, et al. · Diabetes · 2016 · Background
PubMed: PMID 26438611 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Kernan WN, Viscoli CM, Furie KL, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 26886418 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Innervation of the heart: An invisible grid within a black box.
Kapa S, DeSimone CV, Asirvatham SJ, et al. · Trends Cardiovasc Med · 2016 · Background
PubMed: PMID 26254961 · NCT06461377 · Diabetes Mellitus, Type 2
Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Jensterle M, Kocjan T, Kravos NA, et al. · Endocr Res · 2016 · Background
PubMed: PMID 25330463 · NCT06243536 · Diabetes Mellitus, Type 2
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
Iepsen EW, Lundgren J, Dirksen C, et al. · Int J Obes (Lond) · 2016 · Background
PubMed: PMID 25287751 · NCT05574439 (RESETTLE) · Weight Loss
Local and systemic effects of the multifaceted epicardial adipose tissue depot.
Iacobellis G · Nat Rev Endocrinol · 2016 · Background
PubMed: PMID 25850659 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.
Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. · Lancet · 2016 · Background
PubMed: PMID 27423262 · NCT05574439 (RESETTLE) · Weight Loss
Multidisciplinary care of obese children and adolescents for one year reduces ectopic fat content in liver and skeletal muscle.
Fonvig CE, Chabanova E, Ohrt JD, et al. · BMC Pediatr · 2016 · Background
PubMed: PMID 26714769 · NCT05574439 (RESETTLE) · Weight Loss
Adverse Effects of GLP-1 Receptor Agonists.
Filippatos TD, Panagiotopoulou TV, Elisaf MS, et al. · Rev Diabet Stud · 2016 · Background
PubMed: PMID 26177483 · NCT06827002 · Obesity
Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
Du Q, Wang YJ, Yang S, et al. · Adv Ther · 2016 · Background
PubMed: PMID 25388240 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Automated pericardium delineation and epicardial fat volume quantification from noncontrast CT.
Ding X, Terzopoulos D, Diaz-Zamudio M, et al. · Med Phys · 2016 · Background
PubMed: PMID 26328952 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Management of obesity.
Bray GA, Frühbeck G, Ryan DH, et al. · Lancet · 2016 · Background
PubMed: PMID 26868660 · NCT06287307 (SEABAR) · Obesity
Characterization of reward and effort mechanisms in apathy.
Bonnelle V, Veromann KR, Burnett Heyes S, et al. · J Physiol Paris · 2016 · Background
PubMed: PMID 24747776 · NCT06363487 (OxSENSE)

2015 (21 papers)

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R, Sirlin CB, Ang B, et al. · Hepatology · 2015 · Trial result
PubMed: PMID 25482832 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.
Yabe D, Seino Y, Fukushima M, et al. · Curr Diab Rep · 2015 · Background
PubMed: PMID 25944304 · NCT07043361 (Semaglutide) · Metabolic Diseases
Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.
Torekov SS, Holst JJ, Ehlers MR, et al. · Diabetes Obes Metab · 2015 · Background
PubMed: PMID 24251641 · NCT05574439 (RESETTLE) · Weight Loss
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh S, Kim JH · Diabetes Metab J · 2015 · Background
PubMed: PMID 26301188 · NCT06243536 · Diabetes Mellitus, Type 2
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
SPRINT Research Group, Wright JT, Williamson JD, et al. · N Engl J Med · 2015 · Background
PubMed: PMID 26551272 · NCT06975111
Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain.
Mogul HR, Freeman R, Nguyen K, et al. · PLoS One · 2015 · Background
PubMed: PMID 25259787 · NCT06975111
Revisional bariatric surgery is more effective for improving obesity-related co-morbidities than it is for reinducing major weight loss.
McKenna D, Selzer D, Burchett M, et al. · Surg Obes Relat Dis · 2015 · Background
PubMed: PMID 24708909 · NCT06287307 (SEABAR) · Obesity
Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery.
Madsbad S, Dirksen C, Holst JJ, et al. · Lancet Diabetes Endocrinol · 2015 · Background
PubMed: PMID 24622719 · NCT06287307 (SEABAR) · Obesity
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Lau J, Bloch P, Schäffer L, et al. · J Med Chem · 2015 · Background
PubMed: PMID 26308095 · NCT06015893 · Alcoholism
Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.
Kim YG, Hahn S, Oh TJ, et al. · Diabetes Obes Metab · 2015 · Background
PubMed: PMID 24655583 · NCT07043361 (Semaglutide) · Metabolic Diseases
Effect of changes in BMI and waist circumference on ambulatory blood pressure in obese children and adolescents.
Hvidt KN, Olsen MH, Ibsen H, et al. · J Hypertens · 2015 · Background
PubMed: PMID 24733029 · NCT05574439 (RESETTLE) · Weight Loss
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.
Filipova EP, Uzunova KH, Vekov TY, et al. · Diabetol Metab Syndr · 2015 · Background
PubMed: PMID 26288659 · NCT06827002 · Obesity
GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.
Færch K, Torekov SS, Vistisen D, et al. · Diabetes · 2015 · Background
PubMed: PMID 25677912 · NCT05574439 (RESETTLE) · Weight Loss
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
Eng C, Kramer CK, Zinman B, et al. · Lancet · 2015 · Background
PubMed: PMID 25220191 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
de Wit HM, Vervoort GM, Jansen HJ, et al. · Diabetologia · 2015 · Background
PubMed: PMID 24947583 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Impact of obesity on infertility in women.
Dağ ZÖ, Dilbaz B · J Turk Ger Gynecol Assoc · 2015 · Background
PubMed: PMID 26097395 · NCT07242534 (SEQ) · Obesity
Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force.
Brethauer SA, Kothari S, Sudan R, et al. · Surg Obes Relat Dis · 2015 · Background
PubMed: PMID 24776071 · NCT06287307 (SEABAR) · Obesity
Selective Impairment of Glucose but Not Fatty Acid or Oxidative Metabolism in Brown Adipose Tissue of Subjects With Type 2 Diabetes.
Blondin DP, Labbé SM, Noll C, et al. · Diabetes · 2015 · Background
PubMed: PMID 25677914 · NCT05419726 · Obesity
The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics.
Beeri MS, Ravona-Springer R, Moshier E, et al. · Alzheimers Dement · 2015 · Background
PubMed: PMID 25150735 · NCT06072963 · Metabolic Syndrome
Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment.
Balcıoğlu AS, Müderrisoğlu H · World J Diabetes · 2015 · Background
PubMed: PMID 25685280 · NCT06461377 · Diabetes Mellitus, Type 2
Pharmacological management of obesity: an endocrine Society clinical practice guideline.
Apovian CM, Aronne LJ, Bessesen DH, et al. · J Clin Endocrinol Metab · 2015 · Background
PubMed: PMID 25590212 · NCT06287307 (SEABAR) · Obesity

2014 (13 papers)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Jensterle Sever M, Kocjan T, Pfeifer M, et al. · Eur J Endocrinol · 2014 · Trial result
PubMed: PMID 24362411 · NCT05702905 · Obesity
Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.
Yosida M, Dezaki K, Uchida K, et al. · Diabetes · 2014 · Background
PubMed: PMID 24824430 · NCT07043361 (Semaglutide) · Metabolic Diseases
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. · J Endocrinol · 2014 · Background
PubMed: PMID 24323912 · NCT06827002 · Obesity
Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women.
Teede HJ, Joham AE, Paul E, et al. · Obesity (Silver Spring) · 2014 · Background
PubMed: PMID 23818329 · NCT05646199 · Polycystic Ovary Syndrome
Body mass index as a determinant of brown adipose tissue function in healthy children.
Robinson L, Ojha S, Symonds ME, et al. · J Pediatr · 2014 · Background
PubMed: PMID 24238856 · NCT05419726 · Obesity
Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines.
Moran LJ, Ko H, Misso M, et al. · Hum Reprod Update · 2014 · Background
PubMed: PMID 23727939 · NCT05646199 · Polycystic Ovary Syndrome
Temperature-acclimated brown adipose tissue modulates insulin sensitivity in humans.
Lee P, Smith S, Linderman J, et al. · Diabetes · 2014 · Background
PubMed: PMID 24954193 · NCT05419726 · Obesity
Weight recidivism post-bariatric surgery: a systematic review.
Karmali S, Brar B, Shi X, et al. · Obes Surg · 2014 · Background
PubMed: PMID 23996349 · NCT06287307 (SEABAR) · Obesity
Epicardial adipose tissue in endocrine and metabolic diseases.
Iacobellis G · Endocrine · 2014 · Background
PubMed: PMID 24272604 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Cardiac autonomic neuropathy in patients with diabetes mellitus.
Dimitropoulos G, Tahrani AA, Stevens MJ, et al. · World J Diabetes · 2014 · Background
PubMed: PMID 24567799 · NCT06461377 · Diabetes Mellitus, Type 2
Glucagon-like peptide-1: glucose homeostasis and beyond.
Cho YM, Fujita Y, Kieffer TJ, et al. · Annu Rev Physiol · 2014 · Background
PubMed: PMID 24245943 · NCT06243536 · Diabetes Mellitus, Type 2
Low cerebral blood flow is associated with lower memory function in metabolic syndrome.
Birdsill AC, Carlsson CM, Willette AA, et al. · Obesity (Silver Spring) · 2014 · Background
PubMed: PMID 23687103 · NCT06072963 · Metabolic Syndrome
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Beiroa D, Imbernon M, Gallego R, et al. · Diabetes · 2014 · Background
PubMed: PMID 24917578 · NCT05419726 · Obesity

2013 (10 papers)

The epidemiology of pancreatitis and pancreatic cancer.
Yadav D, Lowenfels AB · Gastroenterology · 2013 · Background
PubMed: PMID 23622135 · NCT06827002 · Obesity
Thermal imaging to assess age-related changes of skin temperature within the supraclavicular region co-locating with brown adipose tissue in healthy children.
Symonds ME, Henderson K, Elvidge L, et al. · J Pediatr · 2013 · Background
PubMed: PMID 22677567 · NCT05419726 · Obesity
Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery.
Sjöström L · J Intern Med · 2013 · Background
PubMed: PMID 23163728 · NCT06287307 (SEABAR) · Obesity
Changes in lipidemia during chronic care treatment of childhood obesity.
Nielsen TR, Gamborg M, Fonvig CE, et al. · Child Obes · 2013 · Background
PubMed: PMID 23181919 · NCT05574439 (RESETTLE) · Weight Loss
Weight loss at first postoperative visit predicts long-term outcome of Roux-en-Y gastric bypass using Duke weight loss surgery chart.
Mor A, Sharp L, Portenier D, et al. · Surg Obes Relat Dis · 2013 · Background
PubMed: PMID 22920966 · NCT06287307 (SEABAR) · Obesity
Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.
Lockie SH, Heppner KM, Chaudhary N, et al. · Diabetes · 2013 · Background
PubMed: PMID 22933116 · NCT05419726 · Obesity
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Jack CR, Knopman DS, Jagust WJ, et al. · Lancet Neurol · 2013 · Background
PubMed: PMID 23332364 · NCT06072963 · Metabolic Syndrome
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.
Gloy VL, Briel M, Bhatt DL, et al. · BMJ · 2013 · Background
PubMed: PMID 24149519 · NCT06287307 (SEABAR) · Obesity
Monocytes in coronary artery disease and atherosclerosis: where are we now?
Ghattas A, Griffiths HR, Devitt A, et al. · J Am Coll Cardiol · 2013 · Background
PubMed: PMID 23973684 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition.
El Khoudary SR, Wildman RP, Matthews K, et al. · Menopause · 2013 · Background
PubMed: PMID 22990755 · NCT06975111

2012 (12 papers)

Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
Permutt Z, Le TA, Peterson MR, et al. · Aliment Pharmacol Ther · 2012 · Trial result
PubMed: PMID 22554256 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
Le TA, Chen J, Changchien C, et al. · Hepatology · 2012 · Trial result
PubMed: PMID 22431131 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome.
Thomson RL, Brinkworth GD, Noakes M, et al. · Hum Reprod · 2012 · Background
PubMed: PMID 22552687 · NCT05646199 · Polycystic Ovary Syndrome
Incretin-based therapies.
Stonehouse AH, Darsow T, Maggs DG, et al. · J Diabetes · 2012 · Background
PubMed: PMID 21707956 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Bariatric surgery and long-term cardiovascular events.
Sjöström L, Peltonen M, Jacobson P, et al. · JAMA · 2012 · Background
PubMed: PMID 22215166 · NCT06287307 (SEABAR) · Obesity
Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes.
Petersen KF, Dufour S, Morino K, et al. · Proc Natl Acad Sci U S A · 2012 · Background
PubMed: PMID 22547801 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Diet and IVF pilot study: short-term weight loss improves pregnancy rates in overweight/obese women undertaking IVF.
Moran L, Tsagareli V, Norman R, et al. · Aust N Z J Obstet Gynaecol · 2012 · Background
PubMed: PMID 21806596 · NCT07242534 (SEQ) · Obesity
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
Lind M, Jendle J, Torffvit O, et al. · Prim Care Diabetes · 2012 · Background
PubMed: PMID 22015237 · NCT06072963 · Metabolic Syndrome
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M, Flint A, Jones KL, et al. · Diabetes Res Clin Pract · 2012 · Background
PubMed: PMID 22446097 · NCT05419726 · Obesity
The structure and function of the glucagon-like peptide-1 receptor and its ligands.
Donnelly D · Br J Pharmacol · 2012 · Background
PubMed: PMID 21950636 · NCT06015893 · Alcoholism
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Craft S, Baker LD, Montine TJ, et al. · Arch Neurol · 2012 · Background
PubMed: PMID 21911655 · NCT06072963 · Metabolic Syndrome
Alterations in energy balance following exenatide administration.
Bradley DP, Kulstad R, Racine N, et al. · Appl Physiol Nutr Metab · 2012 · Background
PubMed: PMID 22735035 · NCT05419726 · Obesity

2011 (5 papers)

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.
Torekov SS, Madsbad S, Holst JJ, et al. · Obes Rev · 2011 · Background
PubMed: PMID 21401851 · NCT05574439 (RESETTLE) · Weight Loss
Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.
Torekov SS, Kipnes MS, Harley RE, et al. · Diabetes Obes Metab · 2011 · Background
PubMed: PMID 21362122 · NCT05574439 (RESETTLE) · Weight Loss
Eating disorders and gastrointestinal peptides.
Tong J, D'Alessio D · Curr Opin Endocrinol Diabetes Obes · 2011 · Background
PubMed: PMID 21157325 · NCT06243536 · Diabetes Mellitus, Type 2
Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide.
Dubé JJ, Amati F, Toledo FG, et al. · Diabetologia · 2011 · Background
PubMed: PMID 21327867 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes?
Amati F, Dubé JJ, Alvarez-Carnero E, et al. · Diabetes · 2011 · Background
PubMed: PMID 21873552 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2

2010 (10 papers)

Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.
Malik SM, Devera ME, Fontes P, et al. · Liver Transpl · 2010 · Trial result
PubMed: PMID 19938117 · NCT06060392 (Sema-Lit) · Diabetes Mellitus
Association of adolescent obesity with risk of severe obesity in adulthood.
The NS, Suchindran C, North KE, et al. · JAMA · 2010 · Background
PubMed: PMID 21063014 · NCT05574439 (RESETTLE) · Weight Loss
Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?
Matthews KA, Crawford SL, Chae CU, et al. · J Am Coll Cardiol · 2010 · Background
PubMed: PMID 20082925 · NCT06975111
Meteorin promotes the formation of GFAP-positive glia via activation of the Jak-STAT3 pathway.
Lee HS, Han J, Lee SH, et al. · J Cell Sci · 2010 · Background
PubMed: PMID 20460434 · NCT06461377 · Diabetes Mellitus, Type 2
High prevalence of obesity in patients with non-functioning adrenal incidentalomas.
Kolańska K, Owecki M, Nikisch E, et al. · Neuro Endocrinol Lett · 2010 · Background
PubMed: PMID 20588242 · NCT07361874 (IMPACT-MACS) · Weight Loss
Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Kielgast U, Holst JJ, Madsbad S, et al. · Curr Diabetes Rev · 2010 · Background
PubMed: PMID 19925391 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Characterization of Meteorin--an evolutionary conserved neurotrophic factor.
Jørgensen JR, Thompson L, Fjord-Larsen L, et al. · J Mol Neurosci · 2010 · Background
PubMed: PMID 19259827 · NCT06461377 · Diabetes Mellitus, Type 2
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK, Lereun C, Wright D, et al. · Pharmacology · 2010 · Background
PubMed: PMID 20616619 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Increased intramuscular lipid synthesis and low saturation relate to insulin sensitivity in endurance-trained athletes.
Bergman BC, Perreault L, Hunerdosse DM, et al. · J Appl Physiol (1985) · 2010 · Background
PubMed: PMID 20299618 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Relationship between coronary artery disease and epicardial adipose tissue quantification at cardiac CT: comparison between automatic volumetric measurement and manual bidimensional estimation.
Bastarrika G, Broncano J, Schoepf UJ, et al. · Acad Radiol · 2010 · Background
PubMed: PMID 20363161 · NCT06557811 (SemaFatCard) · Diabetes Mellitus

2009 (9 papers)

Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.
Lansberg MG, Schrooten M, Bluhmki E, et al. · Stroke · 2009 · Trial result
PubMed: PMID 19372447 · NCT07030621 (STARS) · Ischemic Stroke
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Sathyapalan T, Cho LW, Kilpatrick ES, et al. · Clin Endocrinol (Oxf) · 2009 · Background
PubMed: PMID 18410553 · NCT05646199 · Polycystic Ovary Syndrome
Ultrasound assessment of gastric content and volume.
Perlas A, Chan VW, Lupu CM, et al. · Anesthesiology · 2009 · Background
PubMed: PMID 19512861 · NCT06154486 · Pneumonia, Aspiration
Effect of acute antidepressant administration on negative affective bias in depressed patients.
Harmer CJ, O'Sullivan U, Favaron E, et al. · Am J Psychiatry · 2009 · Background
PubMed: PMID 19755572 · NCT06363487 (OxSENSE)
Effects of the menopause transition and hormone use on cognitive performance in midlife women.
Greendale GA, Huang MH, Wight RG, et al. · Neurology · 2009 · Background
PubMed: PMID 19470968 · NCT06975111
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Defronzo RA · Diabetes · 2009 · Background
PubMed: PMID 19336687 · NCT06243536 · Diabetes Mellitus, Type 2
Identification and importance of brown adipose tissue in adult humans.
Cypess AM, Lehman S, Williams G, et al. · N Engl J Med · 2009 · Background
PubMed: PMID 19357406 · NCT05419726 · Obesity
Surgery for obesity.
Colquitt JL, Picot J, Loveman E, et al. · Cochrane Database Syst Rev · 2009 · Background
PubMed: PMID 19370590 · NCT06287307 (SEABAR) · Obesity
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
Chen Y, Zhou K, Wang R, et al. · Proc Natl Acad Sci U S A · 2009 · Background
PubMed: PMID 19237574 · NCT06072963 · Metabolic Syndrome

2008 (11 papers)

Impact of obesity on the risk for polycystic ovary syndrome.
Yildiz BO, Knochenhauer ES, Azziz R, et al. · J Clin Endocrinol Metab · 2008 · Background
PubMed: PMID 17925334 · NCT05646199 · Polycystic Ovary Syndrome
The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.
Thomson RL, Buckley JD, Noakes M, et al. · J Clin Endocrinol Metab · 2008 · Background
PubMed: PMID 18583464 · NCT05646199 · Polycystic Ovary Syndrome
Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.
Shaw LJ, Bairey Merz CN, Azziz R, et al. · J Clin Endocrinol Metab · 2008 · Background
PubMed: PMID 18182456 · NCT05646199 · Polycystic Ovary Syndrome
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
Reger MA, Watson GS, Green PS, et al. · J Alzheimers Dis · 2008 · Background
PubMed: PMID 18430999 · NCT06072963 · Metabolic Syndrome
Relation among left ventricular mass, insulin resistance, and hemodynamic parameters in type 2 diabetes.
Ozasa N, Furukawa Y, Morimoto T, et al. · Hypertens Res · 2008 · Background
PubMed: PMID 18497461 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders.
Johnson NA, Walton DW, Sachinwalla T, et al. · Hepatology · 2008 · Background
PubMed: PMID 18393289 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation.
Janssen I, Powell LH, Crawford S, et al. · Arch Intern Med · 2008 · Background
PubMed: PMID 18663170 · NCT06975111
Obese men respond to cognitive but not to catabolic brain insulin signaling.
Hallschmid M, Benedict C, Schultes B, et al. · Int J Obes (Lond) · 2008 · Background
PubMed: PMID 17848936 · NCT06072963 · Metabolic Syndrome
The Lawton instrumental activities of daily living scale.
Graf C · Am J Nurs · 2008 · Background
PubMed: PMID 18367931 · NCT06072963 · Metabolic Syndrome
Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited.
Dubé JJ, Amati F, Stefanovic-Racic M, et al. · Am J Physiol Endocrinol Metab · 2008 · Background
PubMed: PMID 18319352 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology.
Beeri MS, Schmeidler J, Silverman JM, et al. · Neurology · 2008 · Background
PubMed: PMID 18765651 · NCT06072963 · Metabolic Syndrome

2007 (3 papers)

Presence of specific 11C-meta-Hydroxyephedrine retention in heart, lung, pancreas, and brown adipose tissue.
Thackeray JT, Beanlands RS, Dasilva JN, et al. · J Nucl Med · 2007 · Background
PubMed: PMID 17873125 · NCT05419726 · Obesity
Quality of life and psychological well being in polycystic ovary syndrome.
Barnard L, Ferriday D, Guenther N, et al. · Hum Reprod · 2007 · Background
PubMed: PMID 17537782 · NCT05646199 · Polycystic Ovary Syndrome
Biology of incretins: GLP-1 and GIP.
Baggio LL, Drucker DJ · Gastroenterology · 2007 · Background
PubMed: PMID 17498508 · NCT06243536 · Diabetes Mellitus, Type 2

2006 (6 papers)

Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans.
Pessiglione M, Seymour B, Flandin G, et al. · Nature · 2006 · Background
PubMed: PMID 16929307 · NCT06363487 (OxSENSE)
The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization.
Heymann AD, Chodick G, Halkin H, et al. · Diabetes Res Clin Pract · 2006 · Background
PubMed: PMID 16112245 · NCT06072963 · Metabolic Syndrome
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ, Nauck MA · Lancet · 2006 · Background
PubMed: PMID 17098089 · NCT05870462 (SEMA-VR) · Diabetes Mellitus, Type 2
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series.
Bovio S, Cataldi A, Reimondo G, et al. · J Endocrinol Invest · 2006 · Background
PubMed: PMID 16699294 · NCT07361874 (IMPACT-MACS) · Weight Loss
5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling.
Antoniades C, Shirodaria C, Warrick N, et al. · Circulation · 2006 · Background
PubMed: PMID 16940192 · NCT06557811 (SemaFatCard) · Diabetes Mellitus
Psychometric properties of the eating attitudes test and children's eating attitudes test in Croatia.
Ambrosi-Randić N, Pokrajac-Bulian A · Eat Weight Disord · 2006 · Background
PubMed: PMID 16682865 · NCT06243536 · Diabetes Mellitus, Type 2

2005 (6 papers)

Use and abuse of HOMA modeling.
Wallace TM, Levy JC, Matthews DR, et al. · Diabetes Care · 2005 · Background
PubMed: PMID 15161807 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome.
Summers SA, Nelson DH · Diabetes · 2005 · Background
PubMed: PMID 15734832 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment.
Maser RE, Lenhard MJ · J Clin Endocrinol Metab · 2005 · Background
PubMed: PMID 16014401 · NCT06461377 · Diabetes Mellitus, Type 2
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
Harder H, Nielsen L, Tu DT, et al. · Diabetes Care · 2005 · Background
PubMed: PMID 15277417 · NCT05419726 · Obesity
1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice.
Gysemans CA, Cardozo AK, Callewaert H, et al. · Endocrinology · 2005 · Background
PubMed: PMID 15637289 · NCT07043361 (Semaglutide) · Metabolic Diseases
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Ahrén B, Schmitz O · Horm Metab Res · 2005 · Background
PubMed: PMID 15655721 · NCT06827002 · Obesity

2004 (2 papers)

Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Harmer CJ, Shelley NC, Cowen PJ, et al. · Am J Psychiatry · 2004 · Background
PubMed: PMID 15229059 · NCT06363487 (OxSENSE)
Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism.
Ascaso JF, Pardo S, Real JT, et al. · Diabetes Care · 2004 · Background
PubMed: PMID 14633821 · NCT06557811 (SemaFatCard) · Diabetes Mellitus

2003 (4 papers)

Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study.
Wu JH, Haan MN, Liang J, et al. · Ann Epidemiol · 2003 · Background
PubMed: PMID 12821276 · NCT06072963 · Metabolic Syndrome
Diabetic autonomic neuropathy.
Vinik AI, Maser RE, Mitchell BD, et al. · Diabetes Care · 2003 · Background
PubMed: PMID 12716821 · NCT06461377 · Diabetes Mellitus, Type 2
Visualization of interscapular brown adipose tissue using (99m)Tc-tetrofosmin in pediatric patients.
Fukuchi K, Ono Y, Nakahata Y, et al. · J Nucl Med · 2003 · Background
PubMed: PMID 14530470 · NCT05419726 · Obesity
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
During MJ, Cao L, Zuzga DS, et al. · Nat Med · 2003 · Background
PubMed: PMID 12925848 · NCT06072963 · Metabolic Syndrome

2002 (3 papers)

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.
Ovalle F, Azziz R · Fertil Steril · 2002 · Background
PubMed: PMID 12057712 · NCT05646199 · Polycystic Ovary Syndrome
Comorbidity of diabetes mellitus and eating disorders: a follow-up study.
Herpertz S, Albus C, Kielmann R, et al. · J Psychosom Res · 2002 · Background
PubMed: PMID 11728508 · NCT06243536 · Diabetes Mellitus, Type 2
A simple method for the isolation and purification of total lipides from animal tissues.
FOLCH J, LEES M, SLOANE STANLEY GH, et al. · J Biol Chem · 2002 · Background
PubMed: PMID 13428781 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2

2001 (2 papers)

Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes.
Goodpaster BH, He J, Watkins S, et al. · J Clin Endocrinol Metab · 2001 · Background
PubMed: PMID 11739435 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction.
Burdge GC, Wright P, Jones AE, et al. · Br J Nutr · 2001 · Background
PubMed: PMID 11177194 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2

2000 (2 papers)

Age differences in short-term retention of rapidly changing information.
KIRCHNER WK · J Exp Psychol · 2000 · Background
PubMed: PMID 13539317 · NCT06363487 (OxSENSE)
Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies.
Flint A, Raben A, Blundell JE, et al. · Int J Obes Relat Metab Disord · 2000 · Background
PubMed: PMID 10702749 · NCT05616052 · Body Weight Changes

1999 (1 paper)

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
Gutzwiller JP, Drewe J, Göke B, et al. · Am J Physiol · 1999 · Background
PubMed: PMID 10233049 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1

1998 (2 papers)

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint A, Raben A, Astrup A, et al. · J Clin Invest · 1998 · Background
PubMed: PMID 9449682 · NCT05574439 (RESETTLE) · Weight Loss
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
Ahrén B · Bioessays · 1998 · Background
PubMed: PMID 9780839 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1

1997 (3 papers)

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA, Holst JJ, Willms B, et al. · Exp Clin Endocrinol Diabetes · 1997 · Background
PubMed: PMID 9285204 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience.
Morris JC, Ernesto C, Schafer K, et al. · Neurology · 1997 · Background
PubMed: PMID 9191756 · NCT06072963 · Metabolic Syndrome
In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy.
Boesch C, Slotboom J, Hoppeler H, et al. · Magn Reson Med · 1997 · Background
PubMed: PMID 9094069 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2

1996 (2 papers)

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites.
Göke R, Larsen PJ, Mikkelsen JD, et al. · Eur J Neurosci · 1996 · Background
PubMed: PMID 8563978 · NCT06072963 · Metabolic Syndrome
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.
Bullock BP, Heller RS, Habener JF, et al. · Endocrinology · 1996 · Background
PubMed: PMID 8770921 · NCT06243536 · Diabetes Mellitus, Type 2

1995 (1 paper)

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.
Elliott RM, Morgan LM, Tredger JA, et al. · J Endocrinol · 1995 · Background
PubMed: PMID 7852887 · NCT06243536 · Diabetes Mellitus, Type 2

1992 (1 paper)

Validating the SF-36 health survey questionnaire: new outcome measure for primary care.
Brazier JE, Harper R, Jones NM, et al. · BMJ · 1992 · Background
PubMed: PMID 1285753 · NCT06975111

1988 (2 papers)

Effects of exercise and lack of exercise on insulin sensitivity and responsiveness.
King DS, Dalsky GP, Clutter WE, et al. · J Appl Physiol (1985) · 1988 · Background
PubMed: PMID 3292505 · NCT07065383 (Re-CHARM) · Diabetes Mellitus, Type 2
Taste and smell perception in depression.
Amsterdam JD, Settle RG, Doty RL, et al. · Biol Psychiatry · 1988 · Background
PubMed: PMID 3676376 · NCT06363487 (OxSENSE)

1987 (1 paper)

Reliability of the activities of daily living scale and its use in telephone interview.
Shinar D, Gross CR, Bronstein KS, et al. · Arch Phys Med Rehabil · 1987 · Background
PubMed: PMID 3662782 · NCT06072963 · Metabolic Syndrome

1985 (1 paper)

Measurement of gastric emptying time by real-time ultrasonography.
Bolondi L, Bortolotti M, Santi V, et al. · Gastroenterology · 1985 · Background
PubMed: PMID 3896910 · NCT06154486 · Pneumonia, Aspiration

1983 (1 paper)

The eating attitudes test: psychometric features and clinical correlates.
Garner DM, Olmsted MP, Bohr Y, et al. · Psychol Med · 1983 · Background
PubMed: PMID 6961471 · NCT06243536 · Diabetes Mellitus, Type 2

1972 (1 paper)

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Friedewald WT, Levy RI, Fredrickson DS, et al. · Clin Chem · 1972 · Background
PubMed: PMID 4337382 · NCT06827002 · Obesity

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 08 May 2026 19:00:18 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).